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Neuronal cell death via apoptosis or necrosis underlies several devastating 
neurodegenerative diseases associated with aging. Mitochondrial dysfunction resulting 
from oxidative or nitrosative stress often acts as an initiating stimulus for intrinsic 
apoptosis or necrosis. These events frequently occur in conjunction with imbalances in 
the mitochondrial fission and fusion equilibrium, although the cause and effect 
relationships remain elusive. In this thesis, I demonstrate in primary rat cerebellar granule 
neurons (CGNs) that oxidative or nitrosative stress induces an N-terminal cleavage of 
optic atrophy-1 (OPA1), a dynamin-like GTPase that regulates mitochondrial fusion and 
maintenance of cristae architecture. This cleavage event is indistinguishable from the N-
terminal cleavage of OPA1 observed in CGNs undergoing caspase-mediated apoptosis 
(Loucks et al., 2009) and results in removal of a key lysine residue (K301) within the 
GTPase domain. OPA1 cleavage in CGNs occurs coincident with extensive 
mitochondrial fragmentation, disruption of the microtubule network, and cell death. In 
contrast to OPA1 cleavage induced in CGNs by removing depolarizing extracellular 
potassium (5K apoptotic conditions), oxidative or nitrosative stress-induced OPA1 
cleavage caused by complex I inhibition or nitric oxide, respectively, is caspase-
independent. N-terminal cleavage of OPA1 is also observed in vivo in aged rat and mouse 
midbrain and hippocampal tissues. We conclude that N-terminal cleavage and subsequent 
inactivation of OPA1 may be a contributing factor in the neuronal cell death processes 
underlying neurodegenerative diseases, particularly those associated with aging. 
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Furthermore, these data suggest that OPA1 cleavage is a likely convergence point for 
mitochondrial dysfunction and imbalances in mitochondrial fission and fusion induced by 
oxidative or nitrosative stress. 
Protein aggregation is a common pathogenic mechanism in diverse 
neurodegenerative disorders.  TAR DNA-binding protein-43 (TDP-43) cytoplasmic 
inclusions are pathological hallmarks of several neurodegenerative diseases, including 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).  
Furthermore, TDP-43 mutations have been identified in both familial and sporadic forms 
of ALS.  Despite evidence linking dysfunction of TDP-43 to neuronal cell death, it is 
currently unknown whether TDP-43-induced toxicity occurs via a gain of function or loss 
of function mechanism. In the present study, I initially examined the effects of either 
overexpression or knockdown of TDP-43 on neuronal survival in vitro.  Overt neuronal 
cell death was not induced by either experimental paradigm. However, it was noted that 
both endogenous and overexpressed TDP-43 partially localized to mitochondria within 
diverse neuronal and astrocytic cell types.  Furthermore, a significant decrease in the 
function of mitochondrial ETC Complex I occurred following TDP-43 knockdown in 
NSC34 motor neuron/neuroblastoma hybrid cells. These data suggest a novel link 
between TDP-43 localization and function and mitochondrial physiology.  
Despite the preponderance of evidence linking TDP-43 dysfunction to neuronal 
cell death, current investigations indicate that the mechanism by which this protein exerts 
its toxicity is very complex.  Furthermore, little insight has been given into the regulation 
of TDP-43 nuclear export and cytoplasmic localization.  Previously, we described that 
TDP-43 consistently localizes to the mitochondria in diverse neuronal cell types.  In 
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addition, siRNA-mediated TDP-43 depletion was associated with a deficit in 
mitochondrial ETC complex I.  In the present study, I report that TDP-43 nuclear export 
is enhanced by reductions in mitochondrial glutathione (GSH) levels.  Accordingly, 
redistribution of TDP-43 from the nucleus to the cytoplasm is induced by ethacrynic acid 
(EA) depletion of cellular glutathione levels, and this effect is inhibited by 
overexpression of the mitochondrial GSH transporter, the 2-oxoglutarate carrier (OGC), 
which specifically increases the mitochondrial GSH pool.  Furthermore, inhibition of c-
Jun N-terminal kinase (JNK) but not p38 MAP kinase effectively ameliorates EA induced 
TDP-43 nuclear export.  These data suggest novel regulation of TDP-43 cellular 
distribution and highlights a relationship between mitochondrial physiology, TDP-43 
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Chapter One: Introduction 
1.1 Mitochondrial dynamics 
1.1.1 Mitochondrial dynamics and fission/fusion machinery 
 
Mitochondria are necessary organelles, whose existence and function are 
indispensable for cell survival.  Although most mitochondrial proteins are encoded in the 
nucleus, there is a subset of proteins that are encoded by the mitochondrial genome.  The 
mitochondria have fundamental roles within the cell, with their primary purpose being to 
produce the cell’s energy in the form of ATP.  This function is partially allowed for by 
the double-membrane bound structure of the mitochondria.  The inner membrane, where 
the energy producing respiratory chain complexes are located, is arranged in folds that 
form the mitochondrial cristae.  Regulation of mitochondrial morphology is fundamental 
in its ability to function, and the importance of this organelle is perhaps highlighted by 
the intricate nature in which mitochondria form and function are maintained within the 
cell. 
Mitochondria are dynamic organelles, whose ever changing nature is an 
interesting contrast to the somewhat static morphology of many other cellular organelles. 
They exist not as individual entities but as a network which ranges from smaller, 
individual units to a more tubular, interconnected system.  The fluctuation between these 
two states is termed “mitochondrial dynamics”, and occurs through the fission and fusion 
of inner and outer membranes of the individual organelles. The overall health of the 
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mitochondria relies on a critical balance of these two opposing forces.   If mitochondrial 
fusion components are impaired, the mitochondria adopt a fragmented morphology as a 
result of unopposed fission processes.  Likewise, if mitochondrial fission components are 
defective, the mitochondria become excessively elongated and dysfunctional due to 
unopposed fusion (Bleazard et al., 1999; Sesaki et al., 1999; Chen et al., 2005).  The state 
of the fission-fusion spectrum varies between cell types and even within the same cell 
type, depending on the biological and energy needs.  For instance, mitochondrial 
morphology changes throughout the cell cycle, containing a longer, interconnected 
morphology during G1/S phases and adopting a more fragmented morphology during 
mitosis (Mitra et al., 2009).   Based on a significant number of studies that substantiate 
the importance of correctly balanced mitochondrial fission and fusion processes, it is 
widely accepted that the function of mitochondrial dynamics goes far beyond simple, 
morphologic regulation of the organelle.  Although the method by which these organelles 
achieve such a dynamic existence is very complex, much has been discovered about the 
proteins which carry out the processes of fission and fusion. 
Mitochondrial Fission 
One of the central purposes of mitochondrial fission is to multiply mitochondrial 
numbers in order to repopulate growing and dividing cells (Youle & van der Bliek, 
2012).  Another, perhaps even more important function of fission properties, is the 
execution of mitochondrial quality control.  As certain components of the mitochondria 
become damaged, mitochondria are able to segregate the dysfunctional portions to a 
“daughter” mitochondrion, which is targeted for destruction through mitophagy, leaving 
the healthy components in the remaining “daughter” mitochondrion (Twig et al., 2008).  
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Under more extreme, irreparable circumstances, mitochondrial fission is tightly coupled 
to complete cellular destruction through the apoptotic cascade.  Accordingly, 
mitochondrial outer membrane permeabilization by Bax is shown to occur concomitantly 
with increased mitochondrial fission.  Furthermore, the mitochondrial fission protein 
DRP1 is shown to co-localize with Bax foci, which precede the release of cytochrome c 
and its initiation of the apoptotic cascade (Suen et al., 2008).  These tightly controlled 
processes underscore the importance the mitochondrial fission machinery in cellular 
function, as well as the complex nature in which fission participates in mitochondrial 
quality control.     
 Mitochondrial fission is carried out by proteins in the dynamin family of 
GTPases.   DRP1 (dynamin-related protein 1) is a central participant in fission events.  It 
assembles on the outer mitochondrial membrane where it uses its dynamin-GTPase 
function to constrict and pinch off the organelle into two separate entities (Bleazard, et al. 
1999; Labrousse, et al. 1999; Sesaki and Jensen, 1999; Smirnova et al., 1999).  Like 
dynamin, DRP1 contains a GTPase domain, a middle domain, and a GTPase effector 
domain (GED) (Fig. 1.1.1A).  Unlike dynamin, however, DRP1 is lacking a plextrin 
homology domain (PH), indicating a need for additional factors at the mitochondria to 
recruit DRP1 to the outer mitochondrial membrane.  Indeed, DRP1 is recruited to the 
outer mitochondrial membrane by a second class of fission proteins such as FIS1, MFF, 
miD49, and MiD51 (reviewed in Chan, 2012) (Fig. 1.1.1b). 
 The DRP1 mitochondrial recruitment machinery is well-defined in yeast systems.  
FIS1 (fission 1) contains a single transmembrane domain which anchors it to the outer 
mitochondrial membrane, while the majority of it remains cytosolically located (Fig. 
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1.1.1A).  In Saccharomyeces cerevisiae, FIS1 is clearly required for recruitment of yeast 
DRP1 ortholog DNM1 to the outer mitochondrial membrane (Mozdy, et al., 2000).  
Additionally, Mdv1 and Caf4 act as scaffolding proteins to bridge the interaction between 
FIS1 and Dnm1 (Tieu et al., 2000; Griffin et al., 2005).  However straightforward the 
mechanism is in yeast, it becomes more perplexing in mammalian systems, as there are 
no mammalian orthologs to Mdv1 and Caf4 (reviewed in Chan, 2012).  The role of 
mammalian FIS1 in recruitment of DRP1 to the mitochondria also appears to be more 
complex in mammalian cells.  As predicted, overexpression of FIS1 in COS-7, Clone 9, 
and HeLa cells  results in fragmented mitochondria, indicative of increased recruitment 
of DRP1 (Yoon et al., 2003; Stojanovski et al., 2004; Yu et al., 2005).  These data are in 
accord with data demonstrating that inhibition of FIS1 in mammalian cells results in 
elongated mitochondria in several mammalian cell lines, seemingly due to a defect in 
DRP1 outer-membrane localization (Yoon et al., 2003; Lee et al., 2004; Stojanovski et 
al., 2004; Koch et al., 2005; Gandre-Babbe and van der Bliek 2008).  Despite the 
evidence for a role of FIS1 in mitochondrial fission, knockdown of FIS1 does not alter 
the localization of DRP1 to the mitochondria in HeLa cells (Lee et al., 2004).  These 
contrasting data are suggestive of complex mechanisms involved in recruitment of DRP1 
to the mitochondria in mammalian cells.  Indeed, other proteins, including MFF and 
MiD49/51, are shown to be involved in DRP1 mitochondrial recruitment (reviewed in 
Chan et al., 2012). 
 Like FIS 1, MFF (mitochondrial fission factor) is a protein anchored to the outer 
mitochondrial membrane (Fig 1.1.1A).  Accordingly, inhibition of MFF results in a more 
elongated mitochondrial morphology (Gandre-Babbe and van der Bliek, 2008).  
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However, unlike knockdown of FIS1, inhibition of MFF does result in decreased 
mitochondrial recruitment of DRP1, indicating that it has a more direct function in this 
process (Otera et al., 2010).  Furthermore, a direct physical association between DRP1 
and MFF has been established (Lee et al., 2004, Otera et al., 2010).  These data 
emphasize an important and direct role of MFF in DRP1 recruitment to the mitochondria.   
 MiD49/51 (MIEF1) (mitochondrial dynamics protein/mitochondrial elongation 
factor 1) also appear to function in DRP1 recruitment to the mitochondria, although the 
exact mechanism by which they act is somewhat unclear (Fig 1.1.1A-B).  One study 
demonstrates that although inhibition of MiD 49 and 51 individually does not affect 
mitochondrial morphology, knockdown of both MiD49 and 51 simultaneously results in 
elongated mitochondria.  This happens concomitantly with a defect in CCCP induced 
(and DRP1 dependent) mitochondrial fragmentation, suggesting the two may act in 
concert in DRP1 function at the mitochondria (Palmer et al., 2011).   However, another 
study demonstrates that knockdown of MIEF1 (MiD 51) alone causes fragmented 
mitochondria, indicative of a fission defect (Zhao et al., 2011).  Both studies reveal that, 
although overexpression of MiD49/51(MIEF1) does result in increased DRP1 
recruitment to the mitochondria, it also causes the mitochondrial network to become 
elongated, indicating that DRP1 may not be active or able to function in its fission role. 
This is further supported by data indicating that fission morphology (and DRP1 GTPase 
activity) is restored upon knockdown of MiD51, suggesting that MiD51 (MIEF1) has a 
pro-fusion function (Zhao et al., 2011).  The picture is further convoluted in that MiD51 
(MIEF1) is demonstrated to associate with the fission protein hFIS1, independent of its 
interaction with DRP1.  Interestingly, the MIEF1 fusion-phenotype is inhibited by 
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overexpression of hFIS1, suggesting that hFIS1 serves to inhibit the anti-fission/pro-
fusion role of MIEF1.  Taken together, it can be surmised that although MiD49/51 
(MIEF1) play a role in recruitment of DRP1 to the mitochondria, they may actually 
inhibit the fission activity of DRP1.  This inhibitory role of MiD51 (MIEF1) is balanced 
by proper expression levels of hFIS1, which may allow for DRP1 to function once 
recruited.  Again, the sensitivity of the fission-fusion equilibrium is highlighted by the 
complexity of the interactions between the various fission components. 
Mitochondrial Fusion 
Mitochondrial fusion is somewhat controlled by the bioenergetic needs of the cell.  
It occurs during metabolically active conditions as a means to perform oxidative 
phosphorylation at maximum efficiency (Youle and van der Bliek, 2012).  However, like 
fission, mitochondrial fusion is a key component of the mitochondrial quality control 
system.  Mitochondria function on a mixture of nuclear encoded proteins and proteins 
encoded by the mitochondrial genome (mtDNA).  Not only are mutations in the 
mitochondrial genome inherited heterogeneously, but spontaneous mutations within a 
single mitochondrion can occur independently of other mitochondria.  In these situations, 
fusion and subsequent content mixing of mitochondria can serve to dilute out damaged 
mitochondrial components through complementation of mutated mtDNA with that of 
wild type mtDNA (Chan, 2012).  Additionally, cellular and mitochondrial function is 
dependent on the coordination of proper ratios between different mitochondrial and 
nuclear components within each mitochondrion in a given cell.  This would not be 
possible without the matrix and membrane content mixing that occurs during 
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mitochondrial fusion (Chan, 2012).  Indeed, mitochondrial fusion allows for a more 
homogenous and cohesive mitochondrial population within a given cell type.   
Fusion of the inner and outer mitochondrial membranes occurs during two distinct 
processes (Song et al. 2009).  The resulting fused mitochondria consist of a mixture of 
the two membranes and matrix components.  Like mitochondrial fission machinery, 
mitochondrial fusion machinery is comprised of members of the dynamin family of 
GTPases.  MFN1 and 2 (Mitofusin) are dynamin GTPases responsible for fusion of the 
outer mitochondrial membrane.  These proteins are tethered to the mitochondria through 
a single transmembrane domain, with cytosolically located heptad repeat regions and 
GTPase domain (Campello et al., 2012; Chan, 2012) (Fig 1.1.1A).  In mouse MFN 1/2 
knockout studies, mitochondria demonstrate a loss of fusion capabilities, resulting in 
mitochondria with a fragmented morphology (Chen et al., 2003; Koshiba et al., 2004; 
Chen et al., 2005;). It is apparent that fusion of the outer mitochondrial membrane is a 
result of interaction between Mitofusins on adjacent mitochondria, as mitochondria 
expressing wild type Mitofusins will not fuse with Mitofusin deficient mitochondria 
(Koshiba et al., 2004; Meeusen et al., 2004).   Hetero- and homo-oligomeric complexes 
form through interactions of antiparallel coiled-coil regions in Mitofusins that are on 
adjacent mitochondria (Koshiba et al., 2004). Further conformational changes, likely the 
result of GTP hydrolysis, mediate the final fusion of the membrane (Fig 1.1.1B).   
  Optic atrophy-1 (OPA1) is a member of the dynamin GTPase family and is the 
major player in fusion of the inner mitochondrial membrane, as well as maintenance of 
cristae architecture.  These events are orchestrated through oligomerization of 
differentially processed forms of OPA1 (named for its involvement in the autosomal 
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dominant disease Optic Atrophy 1) (Olichon et al., 2003; Cipolat et al., 2004) (Fig. 
1.1.1B).  It is the mammalian ortholog of yeast Mgm1, which was found to have a 
necessary role in fusion of the inner mitochondrial membrane in yeast (Wong et al., 2000; 
Sesaki et al., 2003).  Depletion or total loss of OPA1 function causes a severe deficit of 
mitochondrial fusion, as indicated by mitochondria with a severely fragmented 
morphology, whereas overexpression of this protein results in elongated mitochondria in 
cells that otherwise have a more punctate mitochondrial morphology (Wong et al., 2000; 
Olichon et al., 2002, 2003; Cipolat et al., 2004; Griparic et al., 2004; Lee et al., 2004; 
Chen et al., 2005; Guillou et al., 2005; Griparic et al., 2007; Song et al., 2007; Song et al., 
2009).  Accordingly, mitochondrial fusion is completely prevented in cells containing 
null alleles of OPA1, further indicating that a shift in the expression of fission-fusion 
components results in a disruption of mitochondrial dynamics (Song et al., 2007; Song et 
al., 2009).  Interestingly, unlike Mitofusin-mediated outer membrane fusion, it is not 
necessary for a functional OPA1 to be present on adjacent membranes for fusion of the 
inner mitochondrial membrane to occur (Song et al., 2009).  This can be partially 
explained by OPA1 being able to directly bind the inner mitochondrial membrane and 
hydrolyze GTP, indicating that OPA1 function in fusion may be, at least somewhat, 
dictated through direct membrane interaction (Ban et al., 2010). 
OPA1 is ubiquitously expressed in mammalian systems, although expression 
patterns vary between organisms and even between tissue types within the same 
organism.  Increased expression levels are observed in metabolically active organs, such 
as, the retina, brain, liver, heart, and pancreas (Alexander et al., 2000; Delettre et al., 
2000; Delettre et al., 2001; Akepati et al., 2008;).  It can be surmised that, given the 
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higher energy demands of these tissues, OPA1 is preferentially expressed to promote the 
mitochondrial dynamics machinery to more of a fusion state, which is shown to be more 
supportive of energy production (Youle and van der Bliek, 2012).   
Although the mitochondrial fusion machinery consists of a smaller number of 
proteins than that of the mitochondrial fission machinery, the regulation of fusion is just 
as complex and sensitive to the relative protein levels of the individual components.  
Moreover, regulation of OPA1 occurs not only through control of expression levels, but 
also through complicated post-translational processing that is even more intricately 


















Fig. 1.1.1 – Schematic of vertebrate mitochondrial fission and fusion components. 
(A) Structural domains of  Dynamin-related protien (DRP1) (blue), Fission 1 (FIS1) 
(green), Mitochondrial fission factor (MFF) (black/gray), mitochondrial dynamics 
protein/mitochondrial elongation factor 1(MiD49/51/MIEF1) (black), Mitofusin 1/2 
(MFN1/2) (red/orange), and Optic Atrophy 1 (OPA1) (red). (B) Schematic of physical 
interactions that facilitate fission and fusion processes.  Mitochondrial fission occurs 
through putative cytoplasmic interactions between DRP1 (blue) and MiD49/51 (MIEF1) 
(black) and/or FIS1 (green), where DRP1 encircles and constricts through its GTPase 
function to  form two new daughter  mitochondria.  Fusion of the outer membrane is 
facilitated through interactions of the cytosolically located heptad repeats (HR)  between 
MFN1 and MFN2 (red/orange).  Fusion of the inner membrane is performed by OPA1 
(red), where the different isoforms also oligomerize to maintain cristae architecture 
(adapted from Campello et al., 2010). TPR=Tetratricopeptide Repeats, GED= GTPase 







Mutations in OPA1 were identified as causal in the neurodegenerative disease 
autosomal dominant optic atrophy 1 (ADOA-1), a progressive blindness disease in which 
patients carry one of several mutations in OPA1.  As a result, they have progressive 
degeneration of the retinal ganglion cells, eventually causing atrophy of the optic nerve 
(Alexander et al., 2000; Delettre et al., 2000).  Although the importance of OPA1 
expression in retinal tissue is pathologically relevant, additional neuronal expression of 
OPA1 has been demonstrated in the motor cortex, the frontal brain, the spinal cord, and 
the cerebellar cortex (Delettre et al., 2001; Misaka et al., 2002; Aijaz et al., 2004). The 
importance of OPA1 expression in neurological function is evident, yet its expression in 
non-neural tissue indicates a widespread function. 
OPA1 Protein domains and processing 
OPA1 is a nuclear encoded member of the dynamin family of GTPases.  As such, 
it contains a GTPase domain, a middle domain and a C-terminal coiled-coil GTPase 
effector domain (GED).  Within the N-terminus of the protein, there is a basic 
mitochondrial import sequence (MIS) followed by three hydrophobic domains and 
another coiled-coil domain (reviewed in Landes et al., 2010) (Fig 1.1.2).  Although the 
structure of OPA1 is not surprising, given that it belongs to the dynamin family of 
proteins, the post-translational processing and regulation of OPA1 elicits an intricate and 
complex story that remains somewhat perplexing.   
OPA1 is assembled from thirty exons, of which exons 4, 4b, and 5b are 
alternatively spliced to yield eight mRNA variants (Delettre et al., 2001). Of note, exons 
4b and 5b contain a hydrophobic transmembrane domain, which alludes to distinctive 
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roles of the alternatively spliced isoforms (Delettre et al., 2007; Duvezin-Caubet et al., 
2007).  Moreover, expression of the eight isoforms is highly tissue specific, indicating the 
necessity of differential processing of OPA1 based on the individual needs of the cell 
(Olichon et al., 2002; Akepati et al., 2008). Upon import into the mitochondria, the 
mitochondrial targeting sequence is cleaved by mitochondrial processing peptidases to 
produce a long (L) isoform (Olichon et al. 2002; Satoh et al., 2003; Ishihara et al., 2006). 
Within the mitochondria, OPA1 undergoes further cleavage at several positions (denoted 
S1 and S2) to yield soluble, short (S) isoforms.  Of note, cleavage at S1 removes exon 4b 
and the preceding two transmembrane domains, whereas cleavage at S2 disrupts exon 5b 
and removes all three transmembrane domains (Fig 1.1.2).  Although the exact driving 
force behind how OPA1 is processed post-transcriptionally is unclear, it does seem to be 
controlled, at least somewhat, at the alternative splicing level, as all isoforms containing 
exon 4b are consistently cleaved into the short isoform (Song et al., 2007).  The long 
isoforms remain anchored to the inner membrane, whereas the shortest isoform is devoid 
of membrane anchoring domains.  OPA1 is constitutively cleaved into the short isoform 
by the ATP-dependent metalloprotease YME1L1 at S2 (Griparic et al., 2007; Song et al., 
2007).  Additional cleavage events are mediated by the m-AAA proteases paraplegin and 
AFG3L1-2 at S1 during loss of mitochondrial membrane potential, and the presenilin-
associated rhomboid-like (PARL) protease during apoptosis (Fig 1.1.2) (Herlan et al., 
2003; Cipolat et al., 2006; Ishihara et al., 2006; Duvezin-Czubet et al., 2007; Griparic et 
al., 2007; Ishihara et al., 2007; Song et al., 2007; Guillery et al., 2008; Merkwirth et al., 
2009). The overlap in actions of these proteases indicates a potential redundancy in their 
functions; this is highlighted by the observation that effective siRNA knock-down of any 
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one of these proteases does not abolish OPA1 processing (Griparic et al., 2007; Guillery 
et al., 2008).  OPA1 functions in fusion and maintenance of cristae architecture relies on 
a critical balance of the various OPA1 spliceforms (and subsequent cleavage forms).  
Any disruption in these events causes a shift in this delicate equilibrium, which can result 
in mitochondrial fragmentation and disruption of the cristae architecture.  Indeed, 
regulation of OPA1 processing is one of the tightly regulated components of the 




Fig. 1.1.2 - Structural domains of OPA1 and exon splice sites.  OPA1 is comprised of 
an N-terminal mitochondrial targeting sequence (MTS) and a transmembrane domain 
(TM).  The GTPase domain is followed by a C-terminal GTPase Effector Domain 
(GED).  Coiled-coil (CC) domains flank the GTPase and GED domains.  Exons 4, 4b, 5, 
and 5b are alternatively spliced to yield different mRNA products.  Exons 4b and 5b 
contain additional transmembrane domains that can be spliced at sites S1 and S2, 




OPA1 in mitochondrial fusion 
It is known that both long and short isoforms of OPA1 are necessary for proper 
mitochondrial fusion to take place in healthy cells.  In fact, it is demonstrated that 
oligomerization of both isoforms is necessary for functional fusion to occur, indicating 
that they interact to facilitate fusion of the inner mitochondrial membrane (Meeusen et 
al., 2006; Song et al., 2007; Tondera et al., 2009).  However, the precise mechanism by 
which OPA1 isoforms mediate mitochondrial fusion seems to be more complex.  
Evidence suggests that OPA1 oligomerization occurs through the coiled-coil domains, 
which is independent of the GTPase function (Akepati et al., 2008).  Yet the GTPase 
domain and function are critical to the role of OPA1 in fusion, as mitochondrial 
fragmentation occurs in ADOA-1 patients containing a mutation in the GTPase domain 
(Spinazzi et al., 2008).  These data suggest that although OPA1 oligomerization and 
GTPase mediated fusion capabilities are tightly coupled, they are each distinct and 
independent functions of the protein.  
OPA1 and cristae architecture and sequestration of cytochrome c 
In addition to its function in mitochondrial fusion, OPA1 has a fundamental role 
in maintenance of mitochondrial cristae architecture. This is highlighted in studies which 
demonstrate that deficits in OPA1 result in disruption of cristae morphology (Olichon et 
al., 2003; Griparic et al., 2004; Frezza et al., 2006).   It is understood that the different 
long and short cleavage products of OPA1 interact and oligomerizes to form complexes 
within the cristae to stabilize the cristae structure (Frezza et al., 2006).  Tightly coupled to 
its role in maintenance of the cristae architecture is the role of OPA1 in sequestration of 
cytochrome c within the mitochondrial intermembrane space (Frezza et al., 2006; 
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Yamaguchi et al., 2008).   This is a critical inhibitory process in the intrinsic apoptotic 
cascade, as release of cytochrome c is considered the initiation of the apoptotic cascade 
(Fig 1.1.3).  As such, disruption in this function of OPA1 is shown to induce the intrinsic 
apoptotic cascade, in addition to causing mitochondrial fragmentation (Olichon et al., 
2003; Cipolat et al., 2004; Lee et al., 2004; Olichon et al., 2007).  Upon induction of 
apoptosis, OPA1 complexes are disrupted.  Cytochrome c is subsequently released from 
the cristae into the cytosol, where it exerts its effects on the apoptotic cascade 
(Yamaguchi et al., 2008).  The exact mode of OPA1 complexes in the retention of 
cytochrome c within the mitochondria is somewhat elusive.  One possible method is that 
OPA1 functions as a diffusion barrier at the cristae junction, where it prevents 
cytochrome c release by physically retaining it within the cristae (Perkins et al., 2009).  
During apoptosis, OPA1 subunits become cleaved, causing disassembly of the complex 
and allowing for passage of cytochrome c into the cytosol.  Additionally, cytochrome c is 
also proposed to be somewhat retained within the cristae through binding the 
mitochondrial inner membrane lipid cardiolipin, which is shown to interact with OPA1. 
This suggests that OPA1-mediated retention of cytochrome c may occur through indirect 





Fig. 1.1.3 - OPA1 oligomerization and sequestration of cytochrome c.  OPA1 
mitochondrial targeting sequence (MTS) is constitutively cleaved upon import into the 
mitochondria.  It can anchor to the inner mitochondrial membrane (IM) through the 
transmembrane domain (TM) (yellow), or exist unanchored upon cleavage of the TM 
domain.   OPA1 homo-oligomerization occurs through the coiled-coil (CC) (blue) 
domains (blue) and facilitates OPA1 fusion of the inner mitochondrial membrane (IM).  
OPA1 maintenance of cristae architecture is achieved through oligomerization of 
membrane anchored long isoforms and unanchored short isoforms.  These associations 
allow an interaction that forms an effective blockade at the cristae junction (CJ) which 
sequesters cytochrome c (pink) within the mitochondrial cristae.  OM= outer 






The role of OPA1 in both fusion and retention of cytochrome c within the 
mitochondria is of critical importance, as it provides a mechanistic link between 
mitochondrial dynamics and apoptosis.  The function of OPA1 is clearly very complex, 
and extends beyond its role in mitochondrial fusion.  In fact, mitochondrial fusion and 
cristae architecture activities of OPA1 seem to be mechanistically distinct.  This is 
highlighted in studies which demonstrate that expression of OPA1 mutants that are 
deficient in their fusion capabilities are still able to sequester cytochrome c and prevent 
apoptosis (Frezza et al., 2006).  Furthermore, expression of disassembly resistant forms 
of OPA1 prevents the complete release of cytochrome c (Yamaguchi et al., 2008).   The 
distinct functions of OPA1 can be isolated to specific OPA1 splice variants, as OPA1 
isoforms including exon 4 are needed for fusion functions, whereas exons 4b and 5 seem 
to be more important for sequestration of cytochrome c (Olichon et al., 2007). The 
importance of both post-transcriptional and post-translational processing of this protein is 
evident, as proper splicing is needed in order for proper cleavage sites to be present.  
Although the mechanisms of OPA1 regulation are beginning to be unraveled, they seem 
to be just as complex as the function of this protein itself. The importance of OPA1 in 
mitochondrial fusion being independent from its role in cytochrome c sequestration is 
underscored by the complexity of how both functions occur, and that neither is 
dispensable for cell survival.   
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OPA1 involvement in mitochondrial defects 
In vitro studies to delineate possible mechanisms by which OPA1 mutations cause 
disease have indicated that down regulation or loss-of-function of OPA1 results in 
mitochondrial fragmentation and disruption of the cristae architecture (Olichon et al., 
2003; Griparic et al., 2004; Frezza et al., 2006).  Specifically, adult mice carrying a 
heterozygous mutant allele of OPA1 contain a more fragmented mitochondrial network 
(Davies et al., 2007).  Moreover, fibroblasts from patients affected by ADOA-1 (resulting 
from a loss-of-function of one OPA1 allele) have a fragmented mitochondrial network 
compared to control individuals (Olichon et al., 2007; Chevrollier et al., 2008; Zanna et 
al., 2008). In addition to effects on mitochondrial morphology, OPA1 deficiency results 
in reduced mitochondrial respiratory capacity and increased susceptibility to apoptosis 
(Olichon et al., 2003; Chen et al., 2005; Frezza et al., 2006).  These data further highlight 
the importance of OPA1 in mitochondrial function, and establish a mechanistic link 
between OPA1 deficiency and mitochondrial mediated cell death. 
 
1.2 Mitochondrial oxidative stress and dysfunction in neurodegeneration 
Neurodegenerative diseases include several illnesses, such as, Amyotrophic 
Lateral Sclerosis (ALS), Alzheimer’s disease (AD), Parkinson’s Diseases (PD), and 
Huntington’s disease (HD).  Despite the diversity in the locations and specific neuronal 
types affected, the pathology of neurodegenerative diseases is consistently linked to 
progressive neuronal cell death.  Mitochondria are critical regulators in the apoptotic 
cascade, and their role in the etiology of neurodegenerative diseases is heavily 
substantiated in literature.  
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1.2.1 Mitochondrial electron transport chain and redox biology 
 
Mitochondria are suppliers of the cells energy in the form of ATP during 
oxidative phosphorylation (OXPHOS).  OXPHOS takes place on the folded inner 
membrane of the mitochondria known as the cristae.   It is here that the machinery of the 
electron transport chain (ETC) exists in several complexes (I-V).  The predominant 
function of the ETC machinery is to use electron transfer through the various ETC 
complexes to create a proton gradient across the inner membrane of the mitochondria.  
This gradient accounts in large part for the mitochondrial membrane potential ( m) 
which can be used as a measurement of mitochondrial health and function.  The force of 
the proton gradient is used to drive the formation of ATP from the addition of a 
phosphate to ADP by ATP synthase, the final complex in the ETC.   
The components of the ETC are large, multi-subunit containing complexes.  
These subunits must perform as individual entities and in a coordinated manner with 
other components for proper functioning of the ETC.  A deficit in any one subunit can 
have catastrophic effects.   The majority of the individual subunits are nuclear encoded; 
however, there are components of the ETC that are encoded by the mitochondrial 
genome.  In fact, the 13 protein encoding genes of the mitochondrial genome are all 
components of the ETC.  This is very significant, as the proper function of the ETC, and 
the entire oxidative phosphorylation process, is reliant on mitochondrially encoded DNA. 
Complex I (NADH dehydrogenase/NADH coenzyme Q oxidoreductase) is 
heavily embedded in the inner membrane of the mitochondria, with a smaller portion 
protruding into the mitochondrial matrix.  Upon binding NADH, Complex I transfers two 
electrons to ubiquinone Q (coenzyme Q10), forming ubiquinol and inducing a 
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conformational change in Complex I, resulting in a net transfer of four protons across the 
inner membrane to the intermembrane space. Complex III (cytochrome c oxidoreductase, 
cytochrome bc1 complex) exists as a dimer and transfers electrons from ubiquinol to 
cytochrome c, allowing it to pump two more protons to the intermembrane space.  
Complex IV (cytochrome c oxidase) receives electrons from cytochrome c and transfers 
them to an oxygen molecule, creating two water molecules and transferring four more 
protons to the intermembrane space.  Complex II (succinate dehydrogenase) is an 
independent entry point for electrons into the ETC.  By oxidizing succinate, it can 
transfer electrons to ubiquinone to be used by Complex III.  It does not transfer protons, 
and thus is not a direct contributor to the proton gradient.  The final step in oxidative 
phosphorylation is the formation of ATP from ADP by Complex V (ATP synthase).  This 
very large (600kDa) multimeric structure uses the proton gradient established by the ETC 
to drive the formation of ATP (Chaban et al., 2014). 
The use of electron transfer to create the proton gradient is vital to the function of 
the ETC.  Despite the highly efficient and intricately coordinated function of the ETC, it 
is inevitable that a subset of electrons “leak” to any electron acceptor within the system.  
If at any point the individual complexes of the ETC are functioning inefficiently, this 
electron leakage will become more substantial.  The presence of electrons in such 
proximity to the high levels of oxygen within the mitochondria can have catastrophic 
effects. Indeed, mitochondria are the main contributors to cellular reactive oxygen 
species (ROS) production (Handy and Loscalzo, 2012).  These, predominantly, are in the 
form of superoxide, (O2
_
which is generated due to electron leakage from the ETC to 
oxygen.    It is estimated that 70%-80% of cellular ROS is produced at the mitochondria, 
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and the majority of these are produced due to electron leakage at Complexes I or III 
(Handy and Loscalzo, 2012).  Once formed, ROS react with and cause damage to lipids, 
proteins, and nucleic acids, including both nuclear and mitochondrial DNA (Cooke et al., 
2003; Evans et al., 2004; Filipcik et al., 2006; Chakravarti et al., 2007).  Damage to 
mitochondrial DNA can lead to dysfunctions in the mitochondrially encoded ETC 
components.  This leads to a catastrophic cycle of increased electron leakage which can 
serve to further amplify the damage to mitochondrial proteins, lipids, and DNA, as well 
as other cellular components and nuclear DNA. 
Due to the inevitable formation of ROS, cells have devised numerous antioxidant 
mechanisms to counteract this process, some of which will be highlighted here.  The 
SOD (superoxide dismutase) family of proteins modulates the conversion of O2
_
 to 
hydrogen peroxide (H2O2).  Once formed, hydrogen peroxide can be further broken down 
to oxygen and water by the catalase enzyme (Handy and Loscalzo, 2012).  The 
copper/zinc-dependent SOD (SOD1) is a member of this family and is mainly located 
cytoplasmically, although it has been found in the mitochondria (Barber et al., 2006).  
This protein is of particular importance in the study of neurodegenerative diseases, as 
mutations are associated with familial form of amyotrophic lateral sclerosis (ALS).  
Another member of this family is the manganese-dependent SOD (SOD2).  This protein 
is shown to be vital in neutralizing mitochondrial ROS (Handy and Loscalzo, 2012).  
Deficiencies in this protein cause early death in neonatal mice, which underscores the 
importance of scavenging mitochondrially produced ROS at their source (Li et al., 1995; 
Lebovitz et al., 1996).   
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Glutathione is another crucial antioxidant in various cellular compartments, 
including the mitochondria.  This system utilizes glutathione peroxidase (GPx) and its co-
factor glutathione (GSH) to convert hydrogen peroxides to water.  During this reaction, 
glutathione (GSH) becomes oxidized to GSSG.  It becomes reduced by glutathione 
reductase (GR) back to glutathione (GSH) (Handy and Loscalzo, 2012).  Maintenance of 
reduced intracellular GSH levels occurs through reduction by glutathione reductase, de 
novo synthesis, or extracellular uptake (Handy and Loscalzo, 2012).  Mitochondrial 
stores of glutathione are achieved through facilitated transport through the dicarboxylate 
(DIC) or 2-oxoglutarate (OGC) inner membrane carriers (Meister, 1995; Soderdahl, 
2003).  The importance of glutathione in regulating mitochondrial ROS is highlighted in 
studies which confirm that deficiency of glutathione levels indeed results in damage to 
the mitochondria as well as an increase in apoptosis (Meister, 1995) (discussed further in 
Section 1.2.3). 
1.2.2 Oxidative stress and mitochondrial dysfunction in the etiology of 
neurodegeneration 
  
Cells of the central nervous system (CNS) have an increased dependency on 
properly functioning mitochondria for energy production due to their high metabolic 
demands.  As such, neurons are particularly sensitive to dysfunctions and impairments 
involving the mitochondria.  This is of central importance in the etiology of 
neurodegenerative disorders. 
Aging has long been regarded as one of the greatest risk factors for the 
development of neurodegenerative diseases.  This is largely due to increased damage to 
various mitochondrial components and mitochondrial DNA (mtDNA) as aging 
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progresses.  Due to the especially high energy demand of neurons, their susceptibility to 
mitochondrial dysfunction can be appreciated.  Critical to this concept is the 
accumulation of damage to mitochondrial components and mtDNA as a result of the 
production of ROS (Lin and Beal 2006). As the damage to mitochondria increases, so 
does the production of ROS (Andreyev et al., 2005).  Accordingly, mtDNA mutations 
linked to enhanced ROS production, including point mutations and deletions, have been 
found to accumulate with age, which results in a decrease in mitochondrial function and 
further production of ROS and mitochondrial damage (Piko et al., 1988; Cortopassi and 
Arnheim, 1990; Corral-Debrinski, et al., 1992; Zhang et al., 1992; Michikawa et al., 
1999; Del Bo, 2002; Krishnan, et al., 2008).  As this cycle progresses, it eventually leads 
to reduced mitochondrial membrane potential ( m) and failure of mitochondrial 
function, ultimately resulting in mitochondrial energy crisis, permeabilization of the 
mitochondrial outer membrane and initiation of the intrinsic apoptotic cell death cascade. 
Mitochondria and neurodegeneration 
Although the exact mechanisms linking aging, mitochondria, and 
neurodegeneration are seemingly complex, it is clear that ROS production and 
mitochondrial dysfunction are involved in the propagation of a catastrophic cycle which 
ultimately leads to induction of apoptosis and neuronal cell death.   This underlying 
connection between mitochondria, oxidative stress, and neurodegeneration is a consistent 
theme found amongst neurodegenerative disorders (DiMauro and Andreu, 2000; Wallace, 
2001). 
Alzheimer’s disease (AD), the most common form of dementia, is most prevalent 
in people over the age of 65.  It is characterized symptomatically by a progressive 
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cognitive decline and histopathologically by amyloid-  (A ) peptide plaques (formed 
through cleavage of amyloid precursor protein (APP)), and neurofibrillary tangles 
containing hyperphosphorylated tau (Lin and Beal, 2006).  The link between AD, 
mitochondrial dysfunction, and oxidative stress is heavily substantiated in literature.  
Damage from ROS precedes plaque formation in mouse models of AD as well as in 
patients exhibiting symptoms of AD (Nunomura et al., 2001; Practico et al., 2001).  
Furthermore, upregulation of genes linked to mitochondrial metabolism and apoptosis is 
also shown to occur early in the disease process (Reddy et al., 2004).  Although the exact 
mechanistic relationship behind oxidative stress and the formation of A plaques and tau-
fibrillary tangles is unclear, it is known that oxidative stress alters processing of both 
APP and tau (Lovell et al., 2004; Tamagno et al., 2005).  Furthermore, expression of APP 
results in its localization to the mitochondrial fraction in vitro.  Here, it induces 
glutathione-sensitive apoptosis, indicating that APP exerts its toxic effects, at least 
partially, through a direct pro-oxidant interaction with the mitochondria (Bartley et al., 
2012). Finally, there is evidence that increased mtDNA damage is also involved in AD 
pathogenesis.  It has been demonstrated that mtDNA obtained from affected regions of 
the brain of AD patients have as much as a 63% increase in mutations, as compared to 
controls (Coskun et al., 2004).  Although the role of mitochondrial dysfunction in the 
etiology of AD is very complex and warrants further evaluation, it is evident that many 
aspects of mitochondrial physiology are involved in AD processes.  
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by 
progressive rigidity, bradykinesia, and tremor.  Its pathological hallmarks include nigral 
degeneration marked by cytoplasmic aggregates called Lewy bodies, which consist of -
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synuclein and ubiquitin-positive inclusions.  Mitochondria have long been linked to PD 
etiology, as a mitochondrial complex I inhibitor, MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) and its metabolite MPP
+
, cause a parkinsonian phenotype in synthetic 
opioid users (Lin and Beal 2006).  Moreover, mitochondrial complex I deficiency and 
glutathione depletion are observed in the substantia nigra of PD patients (Schapira et al. 
1990).   
In addition to mitochondrial Complex I inhibition being closely linked to the 
development of PD, the histopathological hallmarks of PD are shown to exist in 
association with mitochondrial dysfunction. Overexpression of -synuclein, a marker of 
Lewy bodies, impairs mitochondrial function and increases oxidative stress in PD mouse 
models (Song et al., 2004).  Additionally, Parkin, an E3 ubiquitin ligase whose 
dysfunction is linked to juvenile onset PD, has an anti-apoptotic effect through its 
interaction with the outer mitochondrial membrane (Darios et al., 2003; Lin and Beal 
2006), whereas Parkin deficiency causes mitochondrial dysfunction and increased 
oxidative stress (Palacino et al. 2004; Pesah et al. 2004). As expected, oxidative damage 
to Parkin impairs its protective qualities and ubiquitin-ligase activities, most likely 
propagating a cycle of further damage (Chung et al., 2004). Finally, overexpression of 
glutathione S-transferase protects against ROS and neurodegeneration phenotypes seen in 
Drosophila Parkin mutants, further implicating that oxidative stress and mitochondrial 
dysfunction are significant factors in neuronal cell death (Whitworth et al., 2005). These 
data are consistent with the common theme in neurodegeneration of mitochondrial 
dysfunction being both a cause and effect in the catastrophic cycle of oxidative stress-
induced cell death. Furthermore, the correlation between PD histopathological findings 
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and mitochondrial deficiency indicates a possible point of convergence in which this 
cycle becomes irreparable. 
Mitochondria and Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease 
characterized by progressive loss of motor neurons in the cortex and spinal cord (Lin and 
Beal 2006).  As motor neuron death ensues, progressive paralysis takes place, with 
patients often succumbing to respiratory failure. Approximately 10% of ALS cases are 
familial, resulting from inherited mutations in various genes.  However, 90% of ALS 
cases are sporadic and are comprised of a varied and complex etiology.  Importantly, in 
both sporadic and familial forms of ALS, post-mortem spinal cord biopsies reveal 
abnormalities in mitochondrial morphology and number (Lin and Beal 2006).  These data 
provide yet another link between mitochondrial dysfunction and neuronal cell death.   
In the G93A mutant SOD1 transgenic mouse model of familial ALS, mice 
demonstrate a defect in mitochondrial energy metabolism at disease onset in the spinal 
cord and brain, as compared to non-neuronal tissue (Mattiazzi et al., 2002).  Under 
normal conditions, SOD1 is predominantly located in the cytoplasm.  However, in ALS 
disease mouse models, mutant SOD1 becomes concentrated within mitochondrially-
located vacuoles, suggesting a link between SOD1 mislocalization and ALS-associated 
mitochondrial deficits (Jaarsma et al., 2001; Liu et al., 2004).  Additional studies 
demonstrate that mitochondrial localization of SOD1 occurs in concert with increased 
oxidative damage to mitochondrial components, impaired ATP synthesis, and diminished 
mitochondrial respiration (Mattiazzi et al., 2002). Importantly, disruptions in 
mitochondrial cristae architecture precede neuronal cell death in mice overexpressing 
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mutant SOD1, strongly suggesting that mitochondrial dysfunction may be a causative 
factor in ALS associated neuronal cell death (Kong and Xu, 1998).  In addition to causing 
direct mitochondrial damage, mutant SOD1 also exerts negative effects through 
sequestering anti-apoptotic proteins, such as BCL2 (Pasinelli et al., 2004).  Accordingly, 
mitochondrial targeting of mutant SOD1 in vitro results in cytochrome c release and 
subsequent apoptosis (Takeuchi et al., 2002).  These data suggest that mutant SOD1 
exerts its toxic effects in a two-fold fashion; first by directly interacting and affecting 
mitochondrial morphology and function through increased oxidative damage and ROS 
production, and second through disrupting anti-apoptotic proteins such as BCL2, thus 
effectively impeding neuronal ability to circumvent the ensuing apoptotic cascade.   
1.2.3 Glutathione and neurodegeneration 
 
Glutathione (GSH) is a necessary component of cellular antioxidant systems.  It 
exists in various parts of the cell to exert its scavenging effects on ROS.  The role of 
glutathione in mitochondrial redox states is one of the vital roles of this small molecule.  
As such, glutathione deficiencies underlie many dysfunctions of the mitochondria, and its 
role in the etiology of neurodegenerative disorders is heavily substantiated.  
Glutathione Synthesis 
Glutathione is a low molecular weight compound, whose thiol group allows it to 
function as a reductant.  Although glutathione exists throughout many cellular 
compartments, its synthesis is restricted solely to the cytoplasm (Lash, 2006).  Synthesis 
of glutathione from its precursor amino acids is ATP-dependent, and is catalyzed by -
glutamylcysteine synthetase and GSH synthetase.  The first and rate-limiting step in 
synthesis combines L-glutamate and L-cysteine using ATP and -glutamylcysteine 
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synthetase to form -glutamyl-L-cysteine.  The second step involves using GSH 
synthetase to combine -glutamyl-L-cysteine and L-glycine to form the final GSH 
product (Lu et al., 1999).  Importantly, the intracellular concentration of L-glutamate is 
much higher than that of L-cysteine.  As such, the availability of the L-cysteine precursor 





Fig. 1.2.4 – Synthesis of glutathione (GSH) is an ATP dependent process that is 
performed by -glutamylcysteine ligase and GSH synthetase combining glutamate, 
cysteine and glycine.  Through the use of GSH peroxidase, glutathione adopts its 
oxidized form, GSSG, while converting H2O2 to water.  Oxidized GSSG is converted 




Glutathione antioxidant function 
A critical function of glutathione is to assist in the reduction of hydrogen peroxide 
(H2O2) produced as a result of aerobic metabolism and increased oxidative stress.  By 
utilizing GSH peroxidase, glutathione adopts its oxidized form, GSSG, while converting 
H2O2 to water.  Oxidized GSSG is converted back to its reduced form by GSSG 
reductase, which utilizes NADPH for this function (Lu, 1999).  
Glutathione uptake into the mitochondria 
Biosynthesis of GSH occurs in the cytoplasm (Griffith and Meister, 1985; 
McKernan et al., 1991).  Therefore, GSH must be transported from the cytoplasm into the 
other cellular compartments once it has been synthesized.  This holds true for the 
mitochondria, whose redox state relies heavily on the presence of GSH.  Due to the 
negatively charged nature of GSH and the negative charge of the mitochondrial matrix, 
glutathione cannot passively diffuse into the mitochondria and therefore must be actively 
imported.  Previous studies in kidney and liver elucidated that the 2-oxoglutarate (OGC; 
Slc25a11) and the dicarboxylate (DIC; Slc25a10) carriers of the inner mitochondrial 
membrane facilitated the import of glutathione (Chen and Lash, 1998; Chen and Lash 
2000; Coll et al., 2003).  However, less is known about neuronal import of mitochondrial 
glutathione.  Studies indicate that inhibition of the tricarboxylate (CIC; Slc25a1) carrier 
effectively inhibits glutathione uptake in rat whole brain mitochondria (Wadey et al., 
2009).  Alternatively, other investigations revealed that rat cortical mitochondria are 
more sensitive to inhibitors of the DIC over that of the OGC.  It is noteworthy that 
inhibition of DIC and the resultant decrease in the uptake of mitochondrial glutathione 
also caused a deficiency in ETC Complex I, further substantiating the importance of 
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mitochondrial GSH levels in maintaining proper function of mitochondrial ETC 
components (Kamga et al., 2010).  Subsequent studies have delineated that the observed 
discrepancies may be due to cell-type specific variations in mitochondrial uptake.  
Indeed, it has been discovered that astrocyte mitochondrial glutathione levels are 
sensitive to both DIC and OGC inhibition, whereas cerebellar granule neuron (CGN) 
levels are only sensitive to DIC inhibition (Wilkins et al., 2013). Furthermore, some 
insight has been given into the mechanism by which mitochondrial glutathione uptake is 
achieved in neurons.  Specifically, it has been demonstrated that BCL-2 facilitates 
mitochondrial uptake of GSH in rat CGNs through a direct GSH-dependent interaction 
with OGC (Wilkins et al., 2012). 
Decreases of Glutathione in neurodegeneration 
The susceptibility of neurons to mitochondrial dysfunction makes it easy to 
appreciate why mitochondrial glutathione levels are imperative for neuronal survival.  
Indeed, decreased mitochondrial glutathione levels have proven to be detrimental during 
the increased oxidative stress that underlies much of the mitochondrial dysfunction found 
in neurodegenerative disorders.  Glutathione related dysfunction and deficiencies are 
interesting to look at in the context of PD, which is characterized by degeneration of the 
substantia nigra.  This area of the brain is particularly prone to oxidative stress for several 
reasons.  Dopamine (DA), which is synthesized in the substantia nigra, can be 
particularly toxic when produced in excess quantities. This is in large part because when 
not immediately taken up by post-synaptic vesicles, it is readily oxidized which can lead 
to the formation of superoxide and hydrogen peroxide (Hastings et al., 1996; Stokes et 
al., 1999). Furthermore, this area of the brain also contains very high levels of iron, which 
33 
can readily react with hydrogen peroxide via the Fenton Reaction to form hydroxyl 
radicals (Sofice et al., 1991).  The intrinsic high propensity of the substantia nigra for 
oxidative stress is further compounded by the fact that this region of the brain contains 
relatively low levels of GSH and glutamylcysteine ligase activity (Kang et al., 1999; 
Pearce et al., 1997; Sian et al., 1994).  Accordingly, a decrease in GSH levels correlates 
with increased oxidative stress in post-mortem analysis of brain tissue from PD patients 
(Dexter et al. 1986; Dexter et al., 1994; Sian et al., 1994; Alam et al., 1997).  Studies 
have eluded to a potential mechanistic link between substantia nigral environment and 
mitochondrial complex I deficiency associated with PD.   In vitro reduction of GSH 
levels specifically results in a complex I deficit (Jha et al., 2000), which provides a 
possible causal association between reduced GSH levels and an acknowledged 
component of the underlying cascade that leads to the development of PD. 
Due to the preponderance of findings linking increased oxidative stress and 
damage to the etiology of PD, antioxidant treatment, such as glutathione 
supplementation, has been an appealing topic in the area of PD treatment research.       
However, clinical studies into GSH supplementation in PD patients have proved to be 
less optimistic, due to the difficulty in drug delivery across the blood brain barrier 
(Smeyne and Smeyne, 2013).  Due to the potential therapeutic effects of GSH 
supplementation, research into a more effective neuronal delivery system may prove to 
be beneficial. 
Like many neurodegenerative diseases, AD pathology is closely linked to 
increased neuronal oxidative damage.  The main pathological hallmarks observed in AD 
are the formation of tau-fibrillary tangles and plaques that consist of A peptides.  
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Although the toxic modalities of A  and associated plaques are seemingly complex, it 
has been demonstrated that A  fragments themselves cause increased oxidative stress 
(Hensley et al., 1994; Markesbery, 1997; Varadarajan et al., 2000; Butterfield et al., 
2013).  It is also demonstrated in vitro that the expression of A  fibrils leads to a decrease 
of GSH levels, which indeed propagates the production of ROS (Abramov et al., 2003; 
Cardoso and Oliveira, 2003). 
Transgenic mouse models of AD display decreased GSH levels in hippocampal 
and cortical neurons prior to the onset of increased ROS levels (Ghosh et al., 2012). 
Interestingly, this model demonstrates an increase in the activity of glutathione 
peroxidase but not glutathione reductase, suggesting that the deficit may come from a 
failure to recycle oxidized GSSG (Resende et al., 2008).  Furthermore, stimulation of 
GSH synthesis increases neuronal survival in mouse models of AD (Ghosh et al., 2014).  
Data from animal models are corroborated in post-mortem analysis of brain samples from 
AD patients, which indicate decreased GSH and GST levels (Lovell et al., 1998; 
Ramassamy et al., 2000; Venkateshappa et al., 2012). Interestingly, glutathione reductase 
and glutathione peroxidase mRNA levels are shown to be increased in post-mortem brain 
analysis of AD patients likely indicating a compensatory mechanism to offset decreased 
GSH levels (Aksenov et al., 1998).  Although the involvement of GSH in the etiology of 
AD is seemingly complex, it is accepted that deficits in GSH levels and/or proteins that 
modulate its turnover play an important role in the pathogenesis of this disease.  In fact, 
decreased levels of GSH can be detected in peripheral blood samples from AD patients 
(Bermejo et al., 2008), indicating the potential to use this as a biomarker for earlier 
disease diagnosis. 
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It is well established that increased oxidative stress and the resultant damage are 
principal components in the pathology of ALS.  Indeed, oxidative damage to lipids, 
proteins and DNA has been observed in spinal cord and motor cortex of sporadic and 
familial forms of ALS (Shaw et al., 1995; Fitzmaurice et al., 1996; Ferrante et al., 1997).  
Furthermore, the involvement of the antioxidant SOD1 in familial ALS substantiates the 
significance of ROS in the pathogenesis of ALS. The obvious correlation between 
increased oxidative damage and both familial and sporadic ALS is indicative of a 
deficiency in antioxidant systems.  Indeed, recent studies demonstrate a trend of 
increased oxidized glutathione in plasma of ALS patients (Baillet et al., 2010).  
Additionally, in vitro models of G93A mutant SOD1 expressing motor neurons display a 
decrease in GSH levels when compared to wild-type control cells (D’Alessandro et al., 
2011). Studies also reveal a decrease of GSH in motor neurons of the G93A mutant 
hSOD1 transgenic mouse model of ALS (Rizzardini et al., 2003).  These results show a 
potential therapeutic approach that could prove to be beneficial in treatment of ALS 
patients; yet, a direct link between reduction in motor neuron GSH levels and ALS 
pathology remains to be established. 
1.3 Trans-activating Response DNA binding Protein/ TARDBP/ TDP-43 
TDP-43 (Trans-activating response DNA binding protein, TARDBP) is a protein 
whose dysfunction is a hallmark of the motor neuron disease ALS and the progressive 
dementia disease known as frontotemporal lobar degeneration/dementia (FTLD) 
(Neumann et al. 2006; Cairns et al., 2007). Interestingly, a portion of both ALS and 
FTLD patients have overlapping symptoms as well as TDP-43 histopathological findings 
in upper and lower motor neuron systems, indicative of a link between these two diseases 
36 
(Lomen-Hoerth et al., 2003; Hodges et al., 2004; Neumann et al., 2006; Cairns et al., 
2007; Riku et al., 2014; reviewed in Chen-Plotkin et al., 2010).  Indeed, TDP-43 
immunoreactive ubiquitin-positive inclusions are found in diseased tissue from both ALS 
and FTLD patients, indicating that these conditions may arise from a similar pathological 
mechanism (Cairns et al., 2006; Neumann et al., 2006; Davidson et al, 2007; Brandmeir 
et al., 2008).  Interestingly, TDP-43 inclusions also occur in other prominent 
neurodegenerative diseases, including AD, PD, and HD (Amador-Ortiz et al, 2007; 
Hasegawa et al., 2007;  Nakashima-Yasuda et al., 2007; Schwab et al., 2008; Uryu et al., 
2008; Arai et al., 2009; reviewed in Chen-Plotkin et al., 2010).  However, despite the 
preponderance of evidence supporting the role of this protein in neurodegeneration, the 
normal functions of TDP-43 have not been fully elucidated.  Furthermore, the 
mechanisms of TDP-43 toxicity in ALS and FTLD are only beginning to be discovered. 
TDP-43 is the main protein element of ubiquitin-positive inclusions found in most 
cases of sporadic and familial ALS (Neumann et al., 2006).  It contains 2 RNA binding 
domains and a C-terminal glycine rich domain.  Based on its structure, it is placed in the 
heterogeneous nuclear ribonuclear protein (hnRNP) family (reviewed in Chen-Plotkin, et 
al., 2010). 
1.3.1 TDP-43 Structure and Function 
 
The functional roles of TDP-43 have only been established in very specific, 
isolated contexts.  TDP-43 was first discovered because of its ability to bind the 
transactive response region of HIV-1, where it represses gene expression (Ou et al., 
1995).  It is known that TDP-43 primarily exists in the nucleus, but is also continuously 
translocated between the nucleus and cytoplasm (Ayala et al., 2008; Winton et al., 2008). 
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Additional functions of TDP-43 include modulation of exon splicing (Buratti et al., 2001; 
Mercado et al., 2005; Ayala et al., 2008), modulation of gene expression through direct 
DNA and RNA binding (Ayala et al., 2005; Acharya and Reddi, 2006; Strong et al., 
2007), and modulation of gene expression through stabilization of mRNA (reviewed in 
Chen-Plotkin et al., 2010).  Recent studies have demonstrated TDP-43’s involvement in 
gene expression through both upregulation and downregulation of select microRNAs 
(miRNAs), either through direct miRNA binding or binding of miRNA processing 
machinery (Buratti et al., 2010; Kawahara et al., 2012; Park et al., 2013, reviewed in Lee 
et al., 2012).  Beyond its role in regulating mRNA levels, TDP-43 has also been shown to 
localize to cytoplasmic RNA granules, presumably indicating that it has some 
involvement in RNA trafficking (Wang et al., 2008).  In addition to direct interactions 
with RNA and DNA, TDP-43 also participates in protein-protein interactions through its 
C-terminal glycine-rich domain, notably with other hnRNP proteins involved in 
alternative splicing (Buratti et al., 2005; D’Ambrogio et al., 2009).  Clearly, it is evident 
that TDP-43 has numerous responsibilities within the cell, most of them seemingly to do 
with modulating some aspect of gene expression.  These regulatory functions are shown 
to be integral in a vast array of cellular activities, from early development to metabolic 
pathways.  As studies into the cellular functions of this protein proceed, it is likely that 
additional functions will become evident.     
Despite the somewhat vague knowledge of TDP-43’s functions, the structure of 
TDP-43 has been well elucidated.  It contains 2 RNA binding domains (RBD) and a C-
terminal glycine rich domain that is indispensable for TDP-43 gene splicing function 
(Ayala et al., 2005; Buratti et al., 2005).  This structure has placed TDP-43 in the 
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heterogeneous nuclear ribonuclear protein (hnRNP) family.  The N-terminus of TDP-43 
contains a nuclear localization signal (NLS), consistent with its predominantly nuclear 
presence (reviewed in Chen-Plotkin et al., 2010; Janssens and Broeckhoven, 2013). TDP-
43 also contains a leucine rich nuclear export signal (NES), which is necessary for TDP-
43 cytoplasmic localization (Winton et al., 2008; Janssens and Broeckhoven, 2013). The 
RBDs of TDP-43 are significantly homologous to that of other hnRNP members, which 
is in contrast to the glycine rich domain that does not share homology (reviewed Chen-




Fig. 1.3.1 - TDP-43 protein domains TDP-43 is comprised of an N-terminal nuclear 
localization signal (NLS) followed by two RNA-binding domains (RBD) and a centrally 
located nuclear export signal (NES).  The glycine rich domain is located at the C-terminal 
end.  Locations of known ALS-associated mutations are indicated by vertical lines.  Of 
note, the majority of disease causing mutations (~29), such as the A315T mutation, are 












1.3.2 TDP-43 aggregation and ubiquitination in ALS 
 
Perhaps the most notable recent finding in regards to ALS pathology is that 
cytoplasmic ubiquitin-positive inclusions of TDP-43 are consistently found in both 
sporadic and most familial forms of the disease (Arai et al., 2006; Neumann et al., 2006; 
Davidson et al., 2007; Dickson et al., 2007; Brandmeir et al., 2008).  Interestingly, TDP-
43/ubiquitin-positive inclusions are not observed in familial cases involving mutant 
SOD1, indicating that disease pathology in these two subsets may arise through a 
different mechanism (Mackenzie et al., 2007; reviewed in Chen-Plotkin et al., 2010).  
The significance of these findings is underscored in that there are very few other 
histopathological consistencies between familial and sporadic forms of ALS.  As such, 
evaluation of the mechanism behind dysregulation and aggregation of TDP-43 has 
become a recent focus in ALS research. 
TDP-43/ubiquitin-positive inclusions were initially observed by Neumann et al. in 
brain and spinal cord motor neurons from both ALS and FTLD patients (Neumann et al., 
2006).  Additionally, it was demonstrated that the aggregated TDP-43 had become 
hyperphosphorylated and cleaved to C-terminal fragments (Arai et al., 2006; Neumann et 
al., 2006).  Subsequent reports confirmed TDP-43 aggregation in the spinal cord and 
various brain regions of ALS and FTLD patients (Davidson et al, 2007; Cairns et al., 
2007; Dickson et al., 2007; Brandmeir et al., 2008;  Geser et al., 2008; Mori et al., 2008; 
Giordana et al., 2010).  Moreover, some of these studies reiterate that TDP-43 inclusions 
are also ubiquitin-positive and/or contain phosphorylated TDP-43 (Cairns et al., 2007; 
Giordana et al., 2010). However, other findings indicate that not all TDP-43 positive 
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aggregates are necessarily ubiquitinated, indicating ubiquitination is a somewhat 
heterogeneous finding, and may not be a causal factor in disease pathology (Brandmeir et 
al., 2007; Mori et al., 2008).  Although there are notable differences in the histopathology 
of TDP-43 aggregation, the one factor that remains consistent is that marked loss of 
nuclear TDP-43 occurs concomitantly with cytoplasmic localization of the protein.         
Despite the preponderance of evidence demonstrating TDP-43 inclusions are an 
almost universal event in the pathophysiology of ALS and FTLD, the mechanism behind 
these events has not been as extensively clarified, and what has been discovered has 
varied between studies.  Giordana et al. revealed that although not all TDP-43 aggregates 
are positive for ubiquitin, there is a fraction of soluble (not aggregated) TDP-43 that is 
phosphorylated, truncated and ubiquitinated (Giordana et al., 2010).  In contrast, TDP-43 
“pre-inclusions” (TDP-43 positive cytoplasmic granules) have been shown to lack 
ubiquitin-positive staining (Cairns et al., 2007; Strong et al., 2007; Giordana et al., 2010).  
Collectively, these data imply that although ubiquitination of TDP-43 can precede 
aggregate formation, it is not necessary for the formation of TDP-43 inclusions.  Despite 
the variable results in evaluation of ubiquitination in TDP-43 inclusions, other studies 
indicate that C-terminal truncation and phosphorylation of TDP-43 are a more consistent 
finding in TDP-43 positive aggregates (Hasegawa 2008; Igaz et al., 2008; Neumann et 
al., 2009).               
C-terminal fragments (20-25 kDa) of TDP-43 are part of the pathological 
hallmark of ALS.  They exist in variable lengths and numbers within insoluble TDP-43 
aggregates, along with full length TDP-43 (reviewed in Lee et al., 2012).   The 
mechanism behind the generation of truncated forms of TDP-43 is not fully known.  
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Intriguingly, TDP-43 contains three caspase-3 consensus sequences, and is also shown to 
be directly cleaved into 25 and 35 kDa fragments by caspase-3 in cell culture systems 
(Zhang et al., 2007; Dormann et al., 2009; Zhang et al., 2009; Nishimoto et al., 2010). 
The involvement of caspases in TDP-43 associated neuronal cell death is a very 
appealing concept and gives some putative mechanistic insight into TDP-43 dysfunction.  
However, it remains to be evaluated whether caspase-3 is responsible for TDP-43 
cleavage in vivo.  Other possible scenarios that could render truncated forms of TDP-43 
would be splice variations, cryptic transcriptional start sites (Nishimoto et al., 2010), or 
that other proteases (e.g., calpains) are responsible for TDP-43 cleavage.  Despite the 
ambiguity in the mechanism behind truncation of TDP-43, it has been clearly 
demonstrated that these C-terminal fragments are more prone to phosphorylation than the 
full-length form of TDP-43, indicating that truncation of TDP-43 may be an upstream 
event to phosphorylation.  Moreover, expression of C-terminal fragments in cell systems 
leads to ubiquitin-positive inclusions containing the truncated TDP-43, as well as 
increased apoptosis, indicating an inherent toxicity of the C-terminal fragments 
themselves (Igaz 2009; Zhang et al., 2009). 
Along with TDP-43 truncation, phosphorylation of this protein is also found in 
disease associated aggregates.  Of note, phosphorylation (most commonly at serine 
residues 409 and 410) occurs in aggregates that contain both full length and C-terminal 
fragments of TDP-43 (Hasegawa et al., 2008; Neumann et al., 2009).  Despite these 
consistent findings, the mechanism of TDP-43 phosphorylation and its relationship to 
aggregate formation is seemingly complex.  In animal models, overexpression of wild-
type full length TDP-43 leads to truncated and phosphorylated TDP-43 aggregates, 
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suggesting that these events may be a mechanism to control protein dosage (Xu et al., 
2010).  Moreover, phosphorylated C-terminal fragments of TDP-43 appear to be more 
resistant to proteosomal degradation than non-phosphorylated fragments, indicating that a 
potential mechanism behind aggregation formation may be through a slowed clearance 
by cellular degradation machinery (Zhang et al., 2010).  Although studies confirming the 
presence of phosphorylated TDP-43 in disease models are repeatedly substantiated, 
evaluation of the toxic effects of phosphorylation elicits a more complex picture. 
Mutation of TDP-43 phosphorylation sites to non-phosphorylatable forms in mutant- 
TDP-43 expressing C. elegans models rescues neurotoxic phenotypes, while mutation of 
phosphorylation sites of WT TDP-43 has little to no effect (Liachko et al., 2010).  
Conversely, expression of non-phosphorylatable TDP-43 in mammalian cells has little 
effect on TDP-43 aggregation while, expression of phospho-mimetic forms of TDP-43 
reveals a dramatic reduction in TDP-43 aggregation.  This is surprising in that it signifies 
a protective effect TDP-43 phosphorylation (Brady et al., 2011).  In accord with the 
variation in data surrounding ubiquitination and truncation of TDP-43, phosphorylation 
also appears to have a complex involvement in TDP-43 aggregate formation.  Although it 
is accepted that these two events are tightly coupled, the underlying mechanisms and 
effects of TDP-43 phosphorylation and aggregate formation remain to be determined. 
1.3.3 TDP-43 Mutations in ALS 
 
Since the discovery of TDP-43 protein inclusions in most cases of ALS, there has 
been an emerging agreement that TDP-43 is mechanistically linked to ALS pathology.  
Accordingly, many mutations in TDP-43 have been discovered that are linked to both 
sporadic and familial forms of ALS (Pesiridis et al., 2009).  Familial ALS associated 
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TDP-43 mutations are inherited in an autosomal dominant manner (Pesiridis et al., 2009).  
Importantly, the majority of disease-associated mutations are found in the glycine-rich 
domain, further signifying the importance of this region in TDP-43 function (Kovacs et 
al., 2009). To date, 29 different disease causing missense mutations have been 
documented, 28 of which are located in the C-terminal glycine-rich domain.  These 
mutations are found to occur in both familial and sporadic forms of ALS, as well as in 
cases of FTLD, further highlighting the mechanistic link between these two diseases 
(Sreedharan et al., 2008; Benajiba et al., 2009; Pesiridis et al., 2009).  Importantly, TDP-
43 mutations are correlated with TDP-43 histopathological hallmarks in ALS patients, 
further supporting a correlation between protein dysfunction and ALS disease pathology 
(Pesiridis et al., 2009).  Although there are limited data into effects of TDP-43 mutations, 
a notable finding is that mutations of another hnRNP protein, fused in sarcoma (FUS), are 
also linked to familial forms of ALS. This further substantiates a causal link between 
dysfunctional RNA regulation and the pathogenesis of ALS, and perhaps provides some 
insight into the mechanism of toxicity of TDP-43 mutations (Kwiatkowski et al., 2009).   
The Ala-315-Thr (A315T) mutation in TDP-43 was initially discovered in a 
genetic screen of families exhibiting an autosomal dominant inheritance of ALS (Glitcho 
et al., 2008).  This residue is highly conserved within the glycine-rich domain, indicative 
of a functional importance.  An evaluation of spinal cord samples from A315T TDP-43 
patients reveals significant TDP-43 histopathology concomitant with extensive neuronal 
loss.  These findings are consistent with what is observed in other ALS cases (Cairns et 
al., 2010).  Unfortunately, studies into the effects of this mutation in mouse models yield 
a somewhat convoluted story.  Wegorzewska et al. (2009) reported that the A315T 
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mutant overexpressing mice developed a neuronal pathology that is reminiscent of ALS.  
In contrast, subsequent studies using this mouse model have been less successful, due to 
the mice succumbing to gastrointestinal inclusions prior to any neurological phenotype 
(Esmaeili et al., 2013; Herdewyn et al., 2014).  Although, complete characterization of 
this mouse model has not occurred,  in vitro studies reveal that overexpression of mutant 
A315T constructs (but not WT TDP-43) in primary motor neuronal cultures is toxic and 
results in TDP-43 inclusions that are consistent with ALS histopathology (Kabashi et al., 
2010).  However, the effects of A315T TDP-43 expressed at physiological levels remain 
to be determined.   Based on the link between mutant TDP-43 and familial ALS the 
importance of further evaluation of the effects of this mutation can be appreciated. 
1.3.4 Loss of Function verses Gain of Function and TDP-43 Toxicity  
 
The involvement of TDP-43 dysfunction in ALS is perhaps the most consistent 
pathological finding in a disease spectrum that is otherwise highly variable.  Like other 
neurodegenerative diseases that carry hallmark cellular pathologies, the cause and effect 
relationships between TDP-43 histopathology and ALS disease etiology is seemingly 
complex and remains to be definitively characterized.  A central challenge to unraveling 
the mechanism involved in TDP-43 mediated toxicity is to ascertain whether toxic effects 
occur in a gain of function (GOF) or loss of function (LOF) manner.  Indeed, current 
literature supports both options, and a dichotomy remains on the answer to this question. 
TDP-43 has been demonstrated to have a role in various stages of gene expression 
through its RNA/DNA binding properties as well as through protein-protein interactions.  
However, these findings have occurred in isolated contexts and are seemingly very 
specific to given cell types.  Furthermore, as new data emerges, it is apparent that TDP-
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43 function likely extends far beyond what is currently described.  As such, ascertaining 
TDP-43 LOF effects, especially in vivo, has proven to be especially challenging.  
Nonetheless, there is evidence supporting that this may be a mechanism behind TDP-43 
mediated-toxicity. 
Perhaps the strongest indicator that TDP-43 toxicity occurs through LOF effects 
is the observation that TDP-43 cytoplasmic inclusions occur concomitantly with nuclear 
clearing of the protein (Neumann et al., 2006).  This is significant in that TDP-43 has 
been shown to exert many of its gene expression effects within the nucleus, such as, 
DNA binding and modulation of RNA splicing.  ALS associated decreases in nuclear 
TDP-43 levels would almost certainly render TDP-43 non-functional in these roles.  
Accordingly, in vitro evidence suggests that even through overexpression of full length 
and C-terminal TDP-43 fragments, TDP-43 aggregation occurs concomitantly with a 
disruption in previously established TDP-43 splicing abilities (Igaz et al., 2009).  This 
indicates that TDP-43 function is in fact impaired under conditions that replicate ALS 
associated TDP-43 pathology.  Interestingly, a recent study demonstrates that expression 
of C-terminal TDP-43 fragments results in TDP-43 aggregates that also contain RNA 
Polymerase II as well as transcription factors Sp1 and CREB, suggesting that the effects 
of loss of function extend beyond that of TDP-43 (Yamashita et al., 2014).  Although it 
remains to be determined, it is an intriguing possibility that additional factors are 
sequestered within TDP-43 inclusions. An important point to be made is that protein 
sequestration opens up the possibility of GOF toxicity from TDP-43 cytoplasmic 
aggregates.  These findings are especially intriguing in that they represent a convergence 
point in LOF and GOF.  
47 
TDP-43 GOF toxicity theories have been significantly investigated as a causal 
factor in ALS-associated neuronal cell death.  This is due, in large part, to the autosomal 
dominant inheritance pattern of TDP-43 mutant linked ALS.  Furthermore, the majority 
of studies that recapitulate ALS-associated TDP-43 histopathological features, both in 
vitro and in vivo, are based on overexpression of either WT or mutant forms of TDP-43.  
The central premise of these theories is that TDP-43 aggregates themselves (or 
cytoplasmic localization) exert neuronal toxicity.  Another possibility is that TDP-43 
toxicity occurs through actions in the cytoplasm that would not normally occur, or would 
occur less substantially, if TDP-43 remained primarily nuclear.  Moreover, aberrant TDP-
43 phosphorylation, as is observed in ALS, could theoretically cause atypical TDP-43 
functions that would have detrimental cellular effects.  As with LOF theories, in vivo and 
in vitro studies are in the early stages of delineating possible GOF effects of TDP-43 
proteinopathy. 
It is well established that overexpression of TDP-43 C-terminal fragments form 
toxic cytoplasmic aggregates that mimic ALS-associated TDP-43 histopathology.  
However, investigations into the mechanism of toxicity have yielded variable results.  It 
is recently described that overexpression of C-terminal fragments of TDP-43 in HEK 
cells does not affect the cellular distribution of endogenous TDP-43, even though TDP-
43 cytoplasmic aggregates are formed.  This suggests that the toxic effects are not due to 
loss of nuclear TDP-43 function in this model (Zhang et al., 2009).  However, this is in 
contrast to studies in neuronal-like NSC-34 cells, demonstrating a loss of nuclear TDP-43 
upon overexpression of C-terminal fragments (Yang et al., 2010), suggesting that results 
are dependent on the experimental systems used.  Interestingly, investigations in primary 
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neuronal cultures indicate that TDP-43 mediated toxicity is not dependent on aggregate 
formation.  Rather, increased cytoplasmic levels of non-aggregated TDP-43 are a better 
indicator of cellular toxicity than decreased nuclear levels (Barmada et al., 2010).  This is 
suggestive that toxicity occurs through aberrant TDP-43 functions in the cytoplasm.    It 
is also demonstrated that TDP-43-mediated toxicity is dependent on RNA-binding 
activity (Voigt et al., 2010), further suggesting that toxicity may be caused by a rogue 
TDP-43 function. 
As with other areas of TDP-43 investigations, the LOF and GOF debate remains a 
central component of current ALS research.  Clearly, evidence exists that supports both 
possibilities.  TDP-43 dysfunction occurs through seemingly complex and variable 
mechanisms, and it is equally likely that TDP-43 mediated toxicity occurs in a very 
complex manner.  This alludes to the possibility that both LOF and GOF effects are 
involved.   However, a more thorough understanding will be possible as TDP-43 









Chapter Two: N-terminal cleavage of the mitochondrial fusion GTPase OPA1 
occurs via a caspase-independent mechanism in cerebellar granule neurons exposed 
to oxidative or nitrosative stress 
2.1 Abstract 
Neuronal cell death via apoptosis or necrosis underlies several devastating 
neurodegenerative diseases associated with aging. Mitochondrial dysfunction resulting 
from oxidative or nitrosative stress often acts as an initiating stimulus for intrinsic 
apoptosis or necrosis. These events frequently occur in conjunction with imbalances in 
the mitochondrial fission and fusion equilibrium, although the cause and effect 
relationships remain elusive. Here, we demonstrate in primary rat cerebellar granule 
neurons (CGNs) that oxidative or nitrosative stress induces an N-terminal cleavage of 
optic atrophy-1 (OPA1), a dynamin-like GTPase that regulates mitochondrial fusion and 
maintenance of cristae architecture. This cleavage event is indistinguishable from the N-
terminal cleavage of OPA1 observed in CGNs undergoing caspase-mediated apoptosis 
(Loucks et al., 2009) and results in removal of a key lysine residue (K301) within the 
GTPase domain. OPA1 cleavage in CGNs occurs coincident with extensive 
mitochondrial fragmentation, disruption of the microtubule network, and cell death. In 
contrast to OPA1 cleavage induced in CGNs by removing depolarizing extracellular 
potassium (5K apoptotic conditions), oxidative or nitrosative stress-induced OPA1 
cleavage caused by complex I inhibition or nitric oxide, respectively, is caspase-
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independent. N-terminal cleavage of OPA1 is also observed in vivo in aged rat and mouse 
midbrain and hippocampal tissues. We conclude that N-terminal cleavage and subsequent 
inactivation of OPA1 may be a contributing factor in the neuronal cell death processes 
underlying neurodegenerative diseases, particularly those associated with aging. 
Furthermore, these data suggest that OPA1 cleavage is a likely convergence point for 
mitochondrial dysfunction and imbalances in mitochondrial fission and fusion induced by 
oxidative or nitrosative stress. 
2.2 Introduction 
It is increasingly clear that aging and neurodegeneration are mechanistically 
linked through oxidative or nitrosative stress, mitochondrial dysfunction, and disruption 
of the mitochondrial fission and fusion equilibrium. Aging is often reported as the 
greatest risk factor for the onset of sporadic neurodegenerative diseases and this 
correlation is largely attributed to mitochondrial dysfunction (Bossy-Wetzel et al., 
2003 and Lin and Beal, 2006). However, the mechanistic interrelationships between 
oxidative or nitrosative stress, mitochondrial dysfunction, and alterations in 
mitochondrial fission and fusion are complex and not well defined. Therefore, identifying 
molecular events which link two or more of these factors to neuronal cell death will help 
unravel the pathological basis of the association between neurodegeneration and aging. 
The aberrant production of ROS and reactive nitrogen species (RNS), or deficits 
in endogenous antioxidant or free radical scavenging systems, appear to be critical factors 
in neurodegenerative disorders and aging. Evidence indicates that increased oxidative or 
nitrosative damage through both ROS and RNS in the substantia nigra likely plays a 
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significant role in dopaminergic cell death in PD (Jenner, 2003). In particular, complex I 
inhibition and the associated mitochondrial oxidative stress are pathogenic in PD and 
have led to the development of several neurotoxin models of this disease including MPTP 
and rotenone (Przedborski and Vila, 2003 and Sherer et al., 2007). Studies of post-
mortem AD brain tissue also reveal the adverse effects of ROS and RNS, including lipid 
peroxidation, increased protein carbonyls, and enhanced peroxynitrite-mediated damage 
(Smith et al., 1997; Lin and Beal, 2006). Similarly, increased protein carbonyls, 3-
nitrotyrosine, and lipid peroxidation have been observed in spinal cord motor neurons 
and CSF of patients with amyotrophic lateral sclerosis (ALS) (Barber and Shaw, 2010). 
Importantly, increased oxidative damage as a result of mitochondrial dysfunction has also 
been demonstrated in aging, indicating a potential pathway where aging and 
neurodegeneration converge (Bossy-Wetzel et al., 2003). 
Mitochondria are essential organelles that participate in diverse functions such as 
ATP production, buffering of intracellular calcium, maintenance of cell survival through 
sequestration of cytochrome c, and apoptotic signaling through the release of pro-
apoptotic factors (Ow et al., 2008; Sheridan and Martin, 2010). Mitochondria exist in a 
dynamic state and their proper function relies on a critical balance of fission and fusion 
events (Detmer and Chan, 2007). Impairment of this delicate balance can lead to 
decreased mitochondrial respiration rates and increased ROS production, leading to a 
catastrophic cycle of further damage and dysfunction (Chen et al., 2005 and Knott et al., 
2008). Neurons are particularly susceptible to impairments in mitochondrial dynamics 
due to their increased energy demands (Detmer and Chan, 2007; Knott et al., 2008). 
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Accordingly, a fundamental link between mitochondrial impairment and 
neurodegeneration is heavily substantiated by current literature (Perry et al., 2002; Lin 
and Beal, 2006). 
Several proteins of the dynamin family of large GTPases are responsible for 
mitochondrial fission and fusion, and disruptions of the fission and fusion machinery 
have been linked to neurodegeneration (Knott et al., 2008; Cho et al., 2010). Optic 
atrophy-1 (OPA1) is a member of this GTPase family and is a major player in fusion of 
the inner mitochondrial membrane and maintenance of cristae architecture, events which 
are orchestrated through oligomerization of differentially processed forms of OPA1. 
Oligomerization of OPA1 is necessary for sequestration of cytochrome c in the 
mitochondrial intermembrane space, and disruption in this function is shown to induce 
the intrinsic apoptotic cascade (Olichon et al., 2003; Cipolat et al., 2004). OPA1 is highly 
expressed in retinal tissue during development and into adulthood (Aijaz et al., 2004). 
The importance of proper OPA1 function is underscored by its involvement in the 
neurodegenerative condition, autosomal dominant optic atrophy type 1, which involves 
mutations in the gene encoding for OPA1 (Delettre et al., 2000). Individuals with this 
disease develop progressive blindness as a result of degeneration of retinal ganglion cells 
and their axons that comprise the optic nerve. A subset of patients exhibit additional 
multi-system neurological deficits as a result of mitochondrial impairment (Amati-
Bonneau et al., 2009). In vitro studies to delineate possible mechanisms by which OPA1 
mutations cause disease have indicated that down regulation or loss-of-function of OPA1 
results in mitochondrial fragmentation and disruption of the cristae architecture. 
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Although the importance of OPA1 expression in retinal tissue is pathologically relevant, 
additional neuronal expression of OPA1 has been demonstrated in the motor cortex, the 
frontal brain, the spinal cord, and the cerebellar cortex (Delettre et al., 2001; Misaka et 
al., 2002; Aijaz et al., 2004). The importance of OPA1 expression in neurological 
function is evident, yet its expression in non-neural tissue indicates a widespread 
function. 
OPA1 exists as eight alternatively-spliced variants (Delettre et al., 2001). Upon 
import into the mitochondria, the mitochondrial targeting sequence is cleaved by 
mitochondrial processing peptidases to produce a long (L) isoform (Ishihara et al., 2006). 
Within the mitochondria, OPA1 undergoes further cleavage at several positions to yield 
soluble, short (S) isoforms. Here, processing of OPA1 becomes more complex. OPA1 is 
constitutively cleaved into a short isoform by the ATP-dependent metalloprotease 
YME1L1 (Griparic et al., 2007; Song et al., 2007). Additional cleavage events are 
mediated by the m-AAA proteases paraplegin and AFG3L1 -2 during loss of 
mitochondrial membrane potential, and the presenilin-associated rhomboid-like (PARL) 
protease during apoptosis (Cipolat et al., 2006; Song et al., 2007; Guillery et al., 2008). 
The overlap in actions of these proteases indicates a potential redundancy in their 
functions; this is highlighted by the observation that effective siRNA knock-down of any 
one of these proteases does not abolish OPA1 processing (Griparic et al., 2007; Guillery 
et al., 2008). 
Differential processing of OPA1 splice variants results in at least five distinct 
isoforms (denoted “a”–“e”), all of which are visible by Western blotting. We previously 
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reported the appearance of a novel, smaller OPA1 cleavage product (denoted “f”) upon 
induction of apoptosis in primary cultures of rat cerebellar granule neurons (CGNs). This 
N-terminal cleavage event removes a critical portion of the GTPase domain including 
K301 and, therefore, GTPase activity would be lost and OPA1 rendered non-functional 
(Loucks et al., 2009). This is evident in the observed fragmentation of the mitochondrial 
network coincident with N-terminal OPA1 cleavage. In CGNs, the N-terminal OPA1 
cleavage induced during apoptosis was demonstrated to be caspase-dependent, yet in 
vitro experiments revealed that caspases were not able to directly cleave OPA1. Our 
current studies reveal that this N-terminal OPA1 cleavage also occurs during oxidative or 
nitrosative stress-induced neuronal cell death, but in a caspase-independent manner. This 
particular cleavage event has yet to be identified within a specific neurodegenerative 
condition; however, we demonstrate that N-terminal cleavage of OPA1 occurs 
spontaneously with advancing age in rat and mouse midbrain and hippocampal tissues. 
These findings further connect mitochondrial dysfunction to aging, a principle risk factor 
for neurodegeneration. 
 
2.3 Materials and Methods 
2.3.1 Materials 
 
The monoclonal antibody to OPA1 (residues 708–830) was obtained from BD 
Biosciences (San Diego, CA, USA). The polyclonal antibody to the C-terminus of OPA1 
(residues 947–960) was prepared as described by Zhu et al. (2003). The polyclonal 
antibody to actin was from Abcam (Cambridge, MA, USA). Horseradish peroxidase-
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linked secondary antibodies and reagents for enhanced chemiluminescence were from GE 
Healthcare (Pittsburgh, PA, USA). MitoTracker Green used to detect mitochondria was 
obtained from Invitrogen (Grand Island, NY, USA). The monoclonal β-tubulin antibody, 
MPP
+
, the pan-caspase inhibitor BOC-D (OMe)-FMK and bovine serum albumin (BSA) 
were from Sigma-Aldrich (St. Louis, MO, USA). A CY3-conjugated secondary antibody 
for immunofluorescence was from Jackson Immunoresearch Laboratories (West Grove, 
PA, USA). Rotenone, sodium nitroprusside (SNP), JNK inhibitor II SP600125, p38MAP 
kinase inhibitor SB 203580, QVD, and ALLN were from CalBiochem (San Diego, CA, 
USA). 
2.3.2 Cell Culture 
 
Primary rat cerebellar granule neurons (CGNs) were prepared as described 
previously (Loucks et al., 2009). Briefly, CGNs were isolated from 7-day-old Sprague-
Dawley rat pups of both sexes, with the addition of cytosine arabinoside (10 μM) after 
24 h in vitro to inhibit non-neuronal cell growth. Experiments were performed after 6–7 
days in vitro (DIV). 
2.3.3 Brain tissue preparation 
 
Rat midbrain, hippocampal, cerebellum and substantia nigra tissues were 
dissected from 4 month-old and 22 month-old Sprague-Dawley rats and immediately 
dounce-homogenized in lysis buffer. Protein lysates were obtained and subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) through 7.5% 
polyacrylamide gels. Resolved proteins were transferred to polyvinylidene difluoride 
(PVDF) membranes (Amersham) and immunoblotted as described in the results section. 
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Mouse midbrain, hippocampal, cerebellum and cortical tissues were dissected from 4 
month-old and 15 month-old female FVB mice. Tissues were homogenized and protein 
lysates obtained as described for rat tissues. 
2.3.4 Cell lysis and immunoblotting 
 
After treatment as described in the Results section, cells were washed once in 
1 mL ice-cold phosphate-buffered saline (PBS) (pH 7.4). Cells were incubated for 10 min 
on ice in lysis buffer (150–200 μl per 35-mm well) prepared as described previously 
(Loucks et al., 2006). The cells were then harvested by scraping and cell debris were 
removed by centrifugation at 6000 g for 2 min. Protein concentration was determined 
using BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) with final 
absorbance of samples measured by a microplate spectrophotometer (BioTek 
PowerWave XS2, Winooski, VT, USA). Whole cell lysates were subjected to SDS-
PAGE through 7.5% polyacrylamide gels. Resolved proteins were transferred to PVDF 
membranes and processed for immunoblot analysis as previously described (Loucks et 
al., 2006). In general, western blots shown are representative of a minimum of three 
independent experiments. 
2.3.5 Immunofluorescence/mitochondrial staining 
 
After treatment as described in the Results section, cells were fixed for 1 h at 
room temperature in 4% paraformaldehyde followed by permeabilization and blocking in 
0.2% Triton X-100 and 5% BSA in 1X PBS (pH 7.4). To obtain microtubule staining, β-
tubulin primary antibody was diluted 1:500 in 2% BSA and 0.2% Triton X-100 in PBS. 
Cells were incubated in the primary antibody for approximately 16 h (overnight) at 4 °C 
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and subsequently washed five times in 1X PBS and placed in CY3-conjugated secondary 
antibody and DAPI diluted in 2% BSA and 0.2% Triton X-100 in PBS. Cells were then 
washed five times in 1X PBS followed by addition of anti-quench (5 mg/ml p-
phenylenediamine in 1X PBS). To obtain mitochondria staining, CGNs were treated as 
described in the Results section and subsequently rinsed in Hanks Balanced Salt Solution 
(HBSS). Cells were incubated for 30 min at 37 °C, 10% CO2in MitoTracker Green dye 
and Hoechst stain diluted in HBSS followed by a HBSS rinse. Fluorescent images of both 
β-tubulin and MitoTracker staining were captured using a Zeiss Axioplan 2 fluorescence 
microscope equipped with a Cooke Seniscam CCD camera and Slidebook image analysis 
software (Intelligent Imaging Innovations, Inc., Denver, CO, USA). Five images per well 
were captured and three experiments were completed per treatment. 
 
2.4 Results 
2.4.1 5K-induced CGN apoptosis triggers caspase-dependent N-terminal OPA1 
cleavage 
 
We have previously revealed a novel N-terminal cleavage of OPA1 which is 
induced by various apoptotic stimuli (Loucks et al., 2009). Specifically, OPA1 cleavage 
is observed in CGNs upon removal of depolarizing potassium and serum (5K conditions) 
for 24 h (Loucks et al., 2009) (Fig. 2.4.1 A; cleavage product is denoted as band “f”). 
Consistent with our previous results, this cleavage product is detectable by Western 
blotting using a monoclonal antibody targeted to an epitope in the middle of the OPA1 
sequence (BD OPA1). Next, we examined OPA1 cleavage using a polyclonal antibody 
directed against the last 14 C-terminal residues. The OPA1 cleavage product is also 
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detected with the C-terminal antibody, indicating that the cleavage event occurs at the N-
terminus of OPA1 (Fig. 2.4.1B). Furthermore, OPA1 cleavage induced under 5K 
conditions was substantially reduced upon incubation with the broad spectrum caspase 
inhibitors BOC and QVD (Fig. 2.4.1 A, B). These results support our previous findings 
that N-terminal cleavage of OPA1 occurs via a caspase-dependent mechanism during 





Fig. 2.4.1 - Removal of depolarizing extracellular potassium (5K) induces N-
terminal cleavage of OPA1 that is caspase-dependent. (A–B) CGNs were incubated 
for 24 h in either control medium (25K+serum) or medium lacking serum and containing 
only 5 mM KCl (5K) +/− broad spectrum caspase inhibitor BOC (10 μM) (A) or QVD 
(10 μM) (B). OPA1 cleavage (Clv) was detected using a monoclonal antibody that 
detects residues 708–830 of OPA1 (BD OPA1) (A) or a polyclonal antibody against the 
C-terminal 14 amino acids, residues 947–960 (C-term) (B). The blots were then stripped 
and reprobed for β-Actin (A) or FAK (B) as loading controls. OPA1 isoforms a–f are 
indicated to the left in (A). p87 fl and p79 fl indicate full length OPA1 isoforms. p71 clv 




2.4.2 Mitochondrial fragmentation occurs in concert with N-terminal cleavage of 
OPA1. 
 
We previously established that the N-terminal cleavage of OPA1 described above 
removes a key residue, K301, which is critical for the GTPase function of OPA1. This 
was determined by performing a size comparison of the OPA1 cleavage product with a 
PCR generated deletion mutant lacking the N-terminal 300 amino acids (Loucks et al., 
2009). To further examine the loss of functionality of OPA1 after N-terminal cleavage, 
we investigated whether 5K treatment elicits increased mitochondrial fragmentation. 
Mitochondria adopt a rounded and fragmented morphology when CGNs are incubated in 
5K for 24 h, as visualized by MitoTracker Green staining. This is in contrast to the 
tubular and interconnected mitochondrial morphology that is characteristic of control 
cells (Fig. 2.4.2 A, B). To further assess cell morphology during induction of apoptosis, 
we evaluated fragmentation of the microtubule network, as visualized by β-tubulin 
immunostaining. CGNs incubated in 5K for 24 h displayed a slight increase in 
fragmentation of the microtubule network, demonstrated by the appearance of punctate 
foci. This is in contrast to the interconnected microtubule network observed in control 
cells (Fig. 2.4.2 C, D). However, the microtubule network of 5K-treated cells did not 
display the degree of fragmentation observed in the mitochondrial networks, indicating 










Fig. 2.4.2 - CGNs display significant mitochondrial fragmentation but minimal 
microtubule disruption following 5Ktreatment.   (A–B) CGNs were treated as in 
Fig.1. Live imaging was performed using MitoTracker to detect mitochondria (green) and 
Hoechst to detect nuclei (blue).  (C–D) CGNs were treated as in (A–B), fixed and 




2.4.3 Complex I inhibition with MPP
+
 induces caspase-independent N-terminal 
cleavage of OPA1 that is otherwise indistinguishable from that observed during 5K-
induced apoptosis 
 
Oxidative stress is implicated as a prominent mechanism of mitochondrial 
dysfunction and neuronal cell death associated with neurodegeneration. We sought to 
determine the effects of various oxidative stressors on the cleavage of OPA1. Initially, we 
exposed CGNs to 1-methyl-4-phenylpyridinium (MPP
+
), a potent inhibitor of complex I 
of the ETC often used to model PD. We have previously shown that MPP
+
 induces CGN 
death independent of caspase activation (Harbison et al., 2011). Following MPP
+
 
treatment, an OPA1 cleavage product was observed that was indistinguishable from that 
produced by 5K. The MPP
+
-induced OPA1 cleavage product was detected by both the 
BD monoclonal and C-terminal specific OPA1 antibodies (Fig. 2.4.3A, B). However, in 
contrast to the caspase-dependent cleavage of OPA1 induced by 5K treatment, OPA1 
cleavage resulting from MPP
+
 treatment was insensitive to the pan-caspase inhibitors 
BOC and QVD (Fig. 2.4.3C). This indicates that OPA1 cleavage induced by oxidative 
stress occurs in a caspase-independent manner, via a mechanism distinct from that 
observed under classically apoptotic conditions (i.e., 5K). Additionally, OPA1 cleavage 
induced by MPP
+
 treatment was not inhibited by co-treatment with the calpain inhibitor 
ALLN (Fig. 2.4.3D), indicating that activation of the protease calpain is not a significant 
factor in the N-terminal cleavage of OPA1. To define a possible role for OPA1 cleavage 
in oxidative stress-induced CGN death, we compared the timing of OPA1 cleavage to cell 
death induced by MPP
+
. OPA1 cleavage was detectable by Western blotting after 10 h of 
MPP
+
 treatment (Fig. 2.4.3E). By comparison, nuclear condensation was first apparent 
 
64 
after 8 h of treatment, with significant nuclear condensation occurring after 12 h of 
exposure to MPP
+
 (Fig. 2.4.3 F). These data indicate that N-terminal OPA1 cleavage 
likely forms part of the cell death cascade and is not merely an end result of overt cell 










Fig 2.4.3 - OPA1 cleavage induced by the complex I inhibitor, MPP
+
, is 
indistinguishable from 5K-induced OPA1 cleavage but is caspase-independent.(A–B) 
CGNs were incubated for 24 h in either control medium (25K+serum), 5K, or medium 
containing the complex I inhibitor MPP
+
 (150 μM ). OPA1 cleavage (Clv) was detected 
by Western blotting using a monoclonal antibody that detects residues 708–830 of OPA1 
(BD OPA1) (A) or an antibody that detects the C-terminal 14 amino acids (B). (C) CGNs 
were incubated in either control medium (25K+serum), 5K, or medium containing 
150 μM MPP
+
 as in (A) +/− pan-caspase inhibitors BOC (10 μm) or QVD (10 μm). 
OPA1 cleavage was detected by Western blotting with a monoclonal antibody to residues 
708-830 of OPA1 (BD OPA1). The blot was then stripped and reprobed for β-Tubulin as 
a loading control. (D) CGNs were treated with MPP
+
 (150 μM) for 24 h +/− the calpain 
inhibitor ALLN or the pan-caspase inhibitor BOC (10 μm). OPA1 cleavage was detected 
as in (A). (E–F) MPP
+
-induced OPA1 cleavage occurs concurrently with nuclear 
condensation. CGNs were incubated for up to 24 h in medium containing MPP
+
 
(150 μM), with OPA1 cleavage evaluated by Western blotting as in (A) at 0, 4, 6, 8, 10, 
and 12 h of treatment. (F) CGNs were incubated in medium containing MPP
+
 (150 μM) 
and nuclear morphology was evaluated using either bright-field microscopy or Hoechst 
stain to detect nuclei at 0, 4, 8 and 12 h of treatment. OPA1 isoforms a–f are indicated to 
the left of each Western blot. p87 fl and p79 fl indicate full length OPA1 isoforms. p71 






 induces striking mitochondrial fragmentation and complete disruption of 
the microtubule network in CGNs 
 
We next investigated whether MPP
+
 treatment had an effect on mitochondrial 
fragmentation similar to 5K treatment. MPP
+
 treatment rendered the mitochondrial 
network of CGNs completely fragmented, with areas of small punctate foci in addition to 
areas of larger mitochondrial aggregates. This change in mitochondrial structure was 
striking in comparison to the interconnected mitochondrial network in control cells (Fig. 
2.4.4A, B). The effects of MPP
+
 on the mitochondrial network appeared more severe than 
those observed with 5K treatment. In addition, the microtubule network was significantly 
more fragmented with MPP
+
 than what was observed during 5K treatment, as revealed by 
very diffuse β-tubulin staining, along with the appearance of tubulin aggregates rather 





Fig. 2.4.4 - MPP
+
 induces striking mitochondrial fragmentation and severe 
microtubule disruption in CGNs. CGNs were incubated for 24 hours in either control 
medium (25K + serum) (A, C) or medium containing 150 μM MPP
+
 (B, D). (A, B) Live 
imaging was performed using MitoTracker to detect mitochondria (green) and Hoechst to 
detect nuclei (blue). (C, D) CGNs were treated as in (A, B), fixed and immunostained for 









2.4.5 Rotenone-induced oxidative stress causes caspase-independent OPA1 cleavage, 
mitochondrial fragmentation, and microtubule disruption 
 
To establish that the results seen with MPP
+
 treatment are a result of complex I 
inhibition and not a different aspect of its toxicity, CGNs were exposed to rotenone, 
another complex I inhibitor. Similar to results of MPP
+
 treatment, rotenone-treated cells 
also displayed cleavage of OPA1 to produce the fragment labeled “f”, which was not 
prevented by co-treatment with the pan-caspase inhibitor QVD (Fig. 5A). These data 
further support the notion that N-terminal cleavage of OPA1 induced by oxidative stress 
occurs in a caspase-independent manner. In addition, rotenone treatment rendered the 
mitochondrial network completely fragmented, demonstrated by scattered areas of small 
punctate foci detected by MitoTracker staining (Fig. 5B, C). Likewise, the microtubule 
network also displayed severe fragmentation comparable to that observed with MPP
+
 














Fig. 2.4.5 - OPA1 cleavage induced by the complex I inhibitor rotenone is caspase-
independent and occurs concurrently with mitochondrial and β-tubulin 
fragmentation. (A) CGNs were incubated for 24 h in either control medium 
(25K+serum) or medium containing ETC complex I inhibitor rotenone (Rot; 10 μM) +/− 
broad spectrum caspase inhibitor QVD (10 μM). OPA1 cleavage was detected by 
Western blotting with a monoclonal antibody to residues 708–830 (BD OPA1). The blot 
was then stripped and reprobed for β-Actin as a loading control. OPA1 isoforms a–f are 
indicated to the left in (A). p87 fl and p79 fl indicate full length OPA1 isoforms. p71 clv 
denotes the cleavage product. (B–E) CGNs were incubated for 24 h in either control 
medium (25K+serum) or medium containing 10 μM rotenone. (B–C) Live imaging was 
performed using MitoTracker to detect mitochondria (green) and Hoechst to detect nuclei 
(blue). (D–E) CGNs were treated as in (B–C), fixed, and immunostained for β-Tubulin 





2.4.6 RNS induces caspase-independent N-terminal cleavage of OPA1, mitochondrial 
fragmentation, and microtubule disassembly 
 
Due to its high relevance to neurodegeneration, we examined the effects of RNS 
on OPA1 cleavage. CGNs were exposed to an overnight treatment with sodium 
nitroprusside (SNP), a nitric oxide donor. As expected, SNP induced N-terminal OPA1 
cleavage that was resistant to co-treatment with the pan-caspase inhibitor QVD (Fig. 6A). 
SNP treatment also caused mitochondria to fragment in a manner similar to treatment 
with complex I inhibitors (Fig. 6B, C). In addition, SNP treatment caused disassembly 
and aggregation of the microtubule network (Fig. 6D, E). Again, this effect was more 
severe than what was observed with 5K treatment. These results indicate that RNS cause 
caspase-independent OPA1 cleavage and associated mitochondrial and microtubule 
fragmentation, similar to what is observed in the presence of ROS generated by inhibition 





        





Fig. 2.4.6- OPA1 cleavage induced by the nitric oxide donor, SNP, is caspase-
independent and occurs concurrently with mitochondrial fragmentation and 
microtubule disassembly. (A) CGNs were incubated for 24 h in either control medium 
(25K+serum) or medium containing the nitric oxide donor sodium nitroprusside (SNP) 
(75 μM) +/− broad spectrum caspase inhibitor QVD (10 μM). OPA1 cleavage was 
detected by Western blotting using a monoclonal antibody to residues 708–830 (BD 
OPA1). The blot was then stripped and reprobed for β-Actin as a loading control. OPA1 
isoforms a–f are indicated to the left in (A). p87 fl and p79 fl indicate full length OPA1 
isoforms. p71 clv denotes the cleavage product. (B–E) CGNs were incubated in either 
control medium (B, D) or medium containing 200 μM SNP (C, E). (B, C) Live imaging 
was performed using MitoTracker to detect mitochondria (green) and Hoechst to detect 
nuclei (blue). (D–E) CGNs were treated as in (B–C), fixed, and immunostained for β-




2.4.7 OPA1 cleavage induced by rotenone is resistant to inhibitors of JNK and p38 
MAP kinases 
 
It is well established that the JNK and p38 MAP kinase pathways are major 
contributors to cell stress responses during oxidative stress-induced apoptosis (Davis, 
2000). More specifically, it has been demonstrated that the JNK and p38 MAP kinase 
pathways are significantly involved in rotenone-induced cell death (Newhouse et al., 
2004). For this reason, we sought to examine the effects of inhibiting these pathways 
under conditions in which N-terminal cleavage of OPA1 occurs. CGNs were exposed 
overnight to rotenone or 5K treatments, with and without a JNK inhibitor (SP600125) or 
a p38 MAP kinase inhibitor (SB239063). Interestingly, these inhibitors attenuated 5K-
induced OPA1 cleavage, although not to the same extent as the pan-caspase inhibitors 
BOC and QVD. This effect is likely due to the capacity of JNK and p38 MAP kinase 
inhibitors to decrease CGN apoptosis in response to 5K treatment and as a result, 
diminish caspase activity. Surprisingly, rotenone-induced OPA1 cleavage was completely 
insensitive to JNK and p38 MAP kinase inhibition (Fig. 2.4.7). These data further support 





          
Fig. 2.4.7 - OPA1 cleavage induced by 5K treatment or rotenone demonstrate 
differential resistance to inhibition of JNK and p38 MAP kinase. CGNs were co-
incubated for 24 h in either control medium (25K+serum), 5K medium, or medium 
containing the complex I inhibitor rotenone (10 μM) +/− the JNK inhibitor II SP600125 
(10 μM) or the p38 MAP kinase inhibitor SB239063 (10 μM). OPA1 cleavage was 
detected by Western blotting using a monoclonal antibody to residues 708–830 (BD 
OPA1). The blot was stripped and reprobed for β-Actin as a loading control. OPA1 
isoforms a–f are indicated to the left. p87 fl and p79 fl indicate full length OPA1 





2.4.8 N-terminal cleavage of OPA1 occurs in aged rat and mouse brain tissues 
 
Increased oxidative damage has been demonstrated to be an attribute of the aging 
process, particularly in the brain. In the preceding results, we consistently demonstrate 
OPA1 cleavage in the presence of various oxidative or nitrosative stressors. Therefore, it 
follows that the increased oxidative stress characteristic of aged brain tissue may 
similarly lead to OPA1 cleavage. To examine this hypothesis, we obtained midbrain and 
hippocampal tissue from young (4 month-old) and aged (22 month-old) rats in order to 
compare processing of endogenous OPA1. Pooled (from 3 rats) midbrain and 
hippocampal tissues from aged rats displayed an OPA1 cleavage product identical in 
molecular weight to that observed under oxidative stress and apoptotic conditions in vitro 
(Fig. 8A). This cleavage product was absent in other aged brain tissues, such as the 
cerebellum and substantia nigra (data not shown). We next examined endogenous OPA1 
cleavage in young (4 month-old) and old (15 month-old) tissues from individual mice. 
Significant endogenous OPA1 cleavage was observed in hippocampus and midbrain but 
not cerebellum and cortex. Of note, there was a considerable increase in endogenous 
OPA1 cleavage observed in aged mouse hippocampal tissue, as compared to other brain 
tissues examined (Fig. 8B, C). These results are consistent with increased oxidative stress 
in aged brain tissue and illustrate that OPA1 cleavage may provide a mechanistic link 












Fig. 2.4.8 - OPA1 cleavage is observed in aged midbrain and hippocampal tissues. 
(A) Midbrain and hippocampal tissues were obtained from young (4 months) or aged (22 
months old) rats, homogenized, and Western-blotted for spontaneous OPA1 cleavage, 
without exposure to exogenous insults. OPA1 was detected by Western blotting with a 
polyclonal antibody to the C-terminal 14 amino acids, residues 947–960 (C-term). Blots 
were then stripped and reprobed for β-Actin as a loading control. (B) Hippocampal, 
midbrain, cerebellum, and cortical tissues were obtained from young (4 months old) or 
aged (15 months old) mice, homogenized as in (A), and Western-blotted for spontaneous 
OPA1 cleavage, without exposure to exogenous insults. OPA1 cleavage was detected by 
Western blotting using a monoclonal antibody to residues 708–830 (BD OPA1). Blots 
were then stripped and reprobed for β-Tubulin as a loading control. OPA1 isoforms a–f 
are indicated to the left. p87 fl and p79 fl indicate full length OPA1 isoforms. p71 clv 
denotes the cleavage product. (C) Relative optical density of band f observed in young 
and aged mouse tissue was obtained for each mouse by calculating the ratio of the density 
of band “f” to band “b”. Results were graphed as mean +/− SEM of each of the three 









Mitochondrial fission and fusion in mammalian cells are controlled by the 
dynamin family GTPases DRP1, OPA1, and the mitofusins, MFN1 and MFN2. The 
OPA1 GTPase has two main functions within mitochondria. First, OPA1 works in 
concert with its binding partner, mitofusin, to promote mitochondrial fusion (Cipolat et 
al., 2004). Second, long and short forms of OPA1 combine within oligomer complexes 
that maintain tight cristae junctions (Frezza et al., 2006). OPA1 plays a critical role in 
each of these functions as demonstrated by the significant mitochondrial fragmentation 
and disruption of the cristae architecture induced by knockdown of OPA1 expression 
(Olichon et al., 2003; Griparic et al., 2004). Imbalances in the fission and fusion 
equilibrium of mitochondria have been linked mechanistically to apoptotic cell death 
pathways. For instance, the pro-apoptotic Bcl-2 family member, Bax, has been shown to 
localize to mitochondrial fission sites and, in the case of nitric oxide-induced apoptosis in 
cortical neurons, requires DRP1 function in order to accumulate in foci along the 
mitochondrial outer membrane (Karbowski et al., 2002; Yuan et al., 2007). Thus, under 
some conditions enhanced mitochondrial fission appears to be required upstream of 
mitochondrial outer membrane permeabilization and cytochrome c release. On the other 
hand, Bcl-2 homology-3 domain (BH3)-only proteins including Bid and Bnip3, disrupt 
OPA1 oligomer formation and act in concert with Bax to induce cristae remodeling and 
promote a maximal release of cytochrome c during induction of apoptosis (Frezza et al., 
2006; Yamaguchi et al., 2008; Landes et al., 2010a; Landes et al., 2010b). Collectively, 
these studies suggest that loss of OPA1 function predisposes cells to apoptosis via two 
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independent pathways including decreased mitochondrial fusion and loosening of cristae 
junctions. Therefore, unraveling the regulation of OPA1 function is essential to 
mechanistically define the link between disruption of mitochondrial fission/fusion and 
induction of apoptosis. 
Proper mitochondrial location within the neuron is mediated via microtubule 
transport. Thus, impairment of this critical network has a direct effect on mitochondrial 
physiology (Saxton and Hollenbeck, 2012). Our data reveal concomitant fragmentation of 
the microtubule and mitochondrial networks during oxidative stress. This is in accord 
with previous literature reporting that peroxynitrite exposure impairs microtubule 
formation (Landino et al., 2002). More specifically, peroxynitrite and hydrogen peroxide 
treatments result in cysteine oxidation of microtubule-associated-protein 2 (MAP2) and 
tau, inhibiting their ability to promote microtubule assembly (Landino et al., 2004). 
Complex I inhibition by MPP
+
 and rotenone have been shown to interfere with 
microtubule assembly through direct binding and destabilizing of tubulin (Marshall and 
Himes, 1978; Cappalletti et al., 2005). Through the establishment that oxidative stress 
insults have direct effects on the microtubule network, it can be inferred that our 
observations of microtubule fragmentation are likely from a similar mechanism. The 
effects of microtubule fragmentation is also linked to perpetuation of the apoptotic 
cascade, through sequestration of pro-apoptotic BH3-only proteins, such as Bim and 
Bmf, thereby limiting their ability to bind pro-survival Bcl-2 proteins (Day et al., 2004). 
This is consistent with reports of apoptotic stimuli disrupting the interaction of the 
cytoplasmic dynein light chain and the potent pro-death Bim, allowing for inhibition of 
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pro-survival Bcl-2 (Puthalakath et al., 1999). Therefore, it is likely that the microtubule 
fragmentation observed in our studies results in a similar perpetuation of apoptotic 
signaling. On the other hand, decreased ATP synthesis resulting from breakdown of 
mitochondrial function will impair the structure of the tubulin network, thereby 
propagating microtubule associated apoptotic signaling (Oropesa et al., 2011). Hence, the 
probability exists that the damage to mitochondria and microtubules observed in our 
studies has a cyclical property which leads to further breakdown of these critical 
networks. 
OPA1 function is largely regulated through post-translational proteolytic 
processing within the mitochondria. A relatively large number of mitochondrial proteases 
including PARL, YME1L1, AFG3L1 -2, Paraplegin, and OMA1, have all been shown to 
cleave OPA1 under certain conditions (Cipolat et al., 2006; Ishihara et al., 2006; Griparic 
et al., 2007; Song et al., 2007; Guillery et al., 2008; Ehses et al., 2009). These cleavage 
events typically result in the processing of long isoforms of OPA1 (denoted “a” and “b” 
on Western blots) into short isoforms (denoted “c”, “d”, and “e” on Western blots). These 
long and short isoforms then interact to form functional OPA1 oligomers that promote 
mitochondrial fusion and cristae architectural integrity (Landes et al., 2010a; Landes et 
al., 2010b). In fact, a non-cleavable long form of OPA1 is unable to induce mitochondrial 
fusion when expressed in OPA1 null cells; however, co-expression of short forms of 
OPA1 restores this fusion capacity (Song et al., 2007). On the other hand, there is also 
ample evidence that aberrant cleavage of OPA1 which produces an overabundance of 
short forms disrupts the mitochondrial fusion machinery leading to fragmentation; a 
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situation that occurs during pathological conditions such as loss of mitochondrial 
membrane potential or induction of apoptosis (Duvezin-Caubet et al., 2006; Ishihara et 
al., 2006). 
Specifically within the context of OPA1 processing during apoptosis, we have 
previously identified a novel N-terminal cleavage of OPA1 that occurs during apoptotic 
conditions in primary cultured CGNs and human neuroblastoma SH-SY5Y cells. This 
cleavage event results in the formation of an N-terminal truncated “short” form of OPA1 
(denoted “f” on Western blots), that is significantly smaller than a deletion mutant of 
OPA1 lacking the N-terminal 300 amino acids (Loucks et al., 2009). Thus, this novel 
short form of OPA1 observed during neuronal apoptosis lacks the critical residue, K301, 
which is essential for the GTPase function of OPA1 (Griparic and van der Bliek, 2005). 
Although this cleavage event was determined to be caspase-dependent, caspases failed to 
directly cleave OPA1 in vitro. In the current study, we reveal an identical OPA1 cleavage 
event that occurs during oxidative and nitrosative stress-induced cell death in CGNs. The 
observed OPA1 cleavage product is indistinguishable from that previously observed 
during classically apoptotic conditions (5K) in CGNs, based on size comparison and 
recognition with both C-terminal specific antibodies and antibodies specific to the middle 
portion of OPA1. However, in contrast to our previous findings, co-incubation with the 
pan-caspase inhibitors, BOC and QVD, failed to inhibit the cleavage of OPA1 induced by 
oxidative or nitrosative stress conditions in CGNs. This result indicates that OPA1 
cleavage occurs in a caspase-independent manner under these conditions, as opposed to 
the caspase-dependent mechanism observed during 5K-induced CGN apoptosis. Notably, 
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we also demonstrate that this OPA1 cleavage product is present in midbrain and 
hippocampal tissues obtained from aged mice and rats (15-month-old, 22-month-old, 
respectively), whereas no OPA1 cleavage product was observed in corresponding tissues 
taken from young (4-month-old) mice or rats. This finding suggests that OPA1 cleavage 
may provide a point of convergence between oxidative stress, mitochondrial dysfunction, 
and aging; a mechanistic link that may be particularly relevant to the enhanced risk of 
neurodegeneration associated with advancing age. 
To date, despite testing a large number of protease inhibitors, we have been 
unable to identify the protease that cleaves OPA1 to generate the novel cleavage product 
(“f”) described above. Based on our previous and current findings, we postulate that two 
distinct mechanisms converge to activate the mitochondrial protease responsible for the 
N-terminal cleavage of OPA1. The first mechanism involves regulation of the unknown 
OPA1 protease by a caspase. Caspase-mediated activation of proteins is well established 
in the apoptotic pathway, such as the activation of executioner caspases by initiator 
caspases or the caspase-8 mediated activation of the pro-apoptotic BH3-only protein Bid 
(Li et al., 1998). In addition, caspases have also been shown to remove the regulatory 
domains of a large number of protein kinases, often resulting in heightened or 
constitutive activation of the kinase (Lee et al., 1997; Takahashi et al., 1998; Chen et al., 
1999; Basu et al., 2002; Huang et al., 2002). Therefore, it is reasonable to hypothesize 
that in the case of caspase-dependent OPA1 cleavage, activated caspases may directly 
cleave a negative regulatory domain of the unidentified OPA1 protease resulting in its 
activation. This is consistent with our observations that caspases are necessary for 
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apoptosis-induced N-terminal cleavage of OPA1, but are incapable of directly cleaving 
OPA1 in vitro (Loucks et al., 2009). The OPA1 cleavage observed under conditions of 
oxidative or nitrosative stress apparently involves activation of the unidentified OPA1 
protease through a caspase-independent mechanism. One possibility is that this protease 
could be activated by an oxidative or nitrosative stress-dependent phosphorylation event. 
However, this seems unlikely since OPA1 cleavage induced by oxidative stress was not 
significantly affected by inhibitors of JNK or p38 MAP kinases. Another possibility is 
that the unidentified OPA1 protease is normally sequestered and maintained in an 
inactive state by its association with the mitochondrial lipid cardiolipin. During 
conditions of oxidative or nitrosative stress, this protease may then become activated by 
the oxidation of cardiolipin, perhaps in a manner similar to cardiolipin oxidation allowing 
for mobilization of cytochrome c (Shidoji et al., 1999). In this context, it is interesting to 
note that anthocyanins, polyphenolic antioxidants found in fruits and vegetables, 
significantly inhibit both cardiolipin oxidation and OPA1 cleavage in CGNs exposed to a 
Bcl-2 inhibitor (Kelsey et al., 2011). Finally, a protease may undergo a direct 
conformational change as a result of oxidation or nitrosylation, resulting in its activation. 
Thus, there are numerous possible mechanisms by which a mitochondrial protease might 
become activated to cleave OPA1 under oxidative or nitrosative stress conditions. Further 
studies, including identification of the precise cleavage site, are necessary in order to 
narrow down the search for the mitochondrial protease involved in generating the novel 
short form (“f”) from OPA1. 
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The relevance of the present findings to neurodegeneration is supported by the 
extensive literature demonstrating a significant impact of pathogenic proteins on the 
mitochondrial fission and fusion machinery in various disease states. For instance, 
alterations in the expression of multiple fission and fusion proteins have been reported in 
AD brain, including a significant reduction in OPA1 (Wang et al., 2009). Moreover, 
oligomeric amyloid-beta-derived diffusible ligands or overproduction of amyloid beta via 
overexpression of Swedish mutant amyloid precursor protein (APPswe), have each been 
shown to induce mitochondrial fragmentation in cultured neuronal cells (Wang et al., 
2008; Wang et al., 2009). In the case of neuronal cells overexpressing APPswe, 
simultaneous OPA1 overexpression rescues the mitochondria from fragmentation. In a 
similar manner, the PD genes, pink1 and parkin, have been shown to negatively regulate 
OPA1 function and induce mitochondrial fission in Drosophila (Deng et al., 2008). In 
accordance with these findings, RNAi-induced knockdown of Pink1 in rat hippocampal 
or midbrain dopaminergic neurons induces hyperfusion of mitochondria, an effect that is 
suppressed by concurrent knockdown of OPA1 (Yu et al., 2011). Finally, mutant 
Huntingtin protein has recently been shown to bind to DRP1 and enhance its GTPase 
activity, resulting in significant mitochondrial fragmentation in neurons in vitro and in 
vivo (Song et al., 2011).  Collectively, these studies suggest that aberrant activation or 
suppression of the mitochondrial fission or fusion machinery likely plays a significant 
pathogenic role in a number of neurodegenerative disorders. Given these findings, it will 
be interesting to determine if aberrant processing of OPA1, particularly the generation of 
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the N-terminal truncated cleavage product described here, occurs in disorders such as 
AD, PD, and Huntington's disease. 
Loss of function of OPA1 has also been linked to mitochondrial dysfunction, 
mitochondrial oxidative stress, and impaired mitochondrial metabolism. For example, 
mutations in OPA1 which are causative in dominant optic atrophy cause reductions in 
ATP synthesis in both fibroblasts and skeletal muscle (Zanna et al., 2008; Lodi et al., 
2011). Furthermore, a subset of patients who exhibit mutations in the highly conserved 
GTPase domain of OPA1 demonstrate multiple phenotypes in addition to progressive 
blindness, such as deafness, ataxia, and neuropathy. These patients also exhibit increased 
mutations in mitochondrial DNA, a condition known to be a hallmark of aging (Amati-
Bonneau et al., 2008). In accordance with these findings in patients, mice displaying 
haploinsufficiency of the OPA1 protein demonstrate pathological features of dominant 
optic atrophy affecting the retinal ganglion cells, but show more subtle neuromuscular 
and metabolic abnormalities as well (Alavi et al., 2007; Alavi et al., 2009). Moreover, 
these mice also display upregulation of NMDA receptors and enhanced oxidative stress 
in the retina (Nguyen et al., 2011). This link between OPA1 loss of function and 
mitochondrial dysfunction and oxidative stress also appears to be significantly associated 
with aging. For instance, OPA1 expression is lower in skeletal muscle of elderly humans 
compared to young controls (Joseph et al., 2012). Additional studies suggest that this 
observation may be more than just correlative since heterozygous mutation of OPA1 in 
Drosophila or deletion of the OPA1 ortholog, Mgm1p, in the yeast S. cerevisiae, induces 
a significant shortening of lifespan in each of these model systems (Tang et al., 2009; 
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Scheckhuber et al., 2011). Given the mechanistic link between OPA1 loss of function, 
mitochondrial dysfunction, oxidative stress, and aging, it is not surprising that we 
observed OPA1 cleavage in aged rat and mouse midbrain and hippocampal tissues. 
OPA1 cleavage to generate the novel short form “f” may in fact be a possible biomarker 
of aging and the declining mitochondrial function associated with this process. 
In summary, we propose a model in which an unidentified mitochondrial protease 
becomes activated as a result of ROS/RNS, increasing age, or through activation of 
caspases as a result of induction of apoptosis. This mitochondrial protease cleaves the N-
terminus of OPA1 removing the key residue K301, and rendering the novel short form of 
OPA1 (“f”) GTPase deficient. This cleavage event results in a loss of OPA1-dependent 
fusion, leading to enhanced mitochondrial fission and dismantling of cristae junctions 
which likely contribute to further mitochondrial dysfunction, oxidative stress, and 
induction of apoptosis. We hypothesize that these mechanisms become more pronounced 
with increasing age as a result of increased ROS/RNS production. Our data suggest that 
aberrant OPA1 cleavage may be a point of convergence that mechanistically links 
impairment of the mitochondrial fission/fusion equilibrium with mitochondrial 
dysfunction, mitochondrial oxidative stress, and neurodegenerative disorders associated 
with aging (Fig. 2.4.9). Future studies aimed at identifying the mitochondrial protease 
responsible for the OPA1 cleavage event described here may reveal a novel molecular 
player in aging and neurodegeneration that could be targeted therapeutically to maintain 






Fig. 2.4.9 - Schematic of proposed OPA1 cleavage mechanism. We propose a 
mechanism in which an unknown protease can become activated through two different 
pathways. One pathway involves a caspase-dependent activation, as observed under 
classically apoptotic conditions (5K). A secondary pathway involves activation of the 
unknown protease in a caspase-independent manner resulting from ROS/RNS stress. 
Upon activation of the protease, OPA1 becomes cleaved, producing a GTPase-deficient, 
non-functional C-terminal fragment. Impairment of proper OPA1 GTPase function 
results in loss of cristae architecture, mitochondrial fragmentation, and ultimately cell 
death. The ensuing breakdown of mitochondrial function causes further increases in 
ROS, resulting in continued cleavage of OPA1 and perpetuation of this cell death 
cascade. Our data demonstrates that OPA1 cleavage occurs spontaneously in aged brain 
tissue, likely resulting from increased oxidative stress that occurs during the aging 
process. OPA1 cleavage in aged brain tissue likely contributes to the cell death cascade 








Chapter Three: TAR-DNA binding protein-43 (TDP-43) localization to 
mitochondria suggests a novel role in modulating mitochondrial physiology 
3.1 Abstract 
 Protein aggregation is a common pathogenic mechanism in diverse 
neurodegenerative disorders.  TAR DNA-binding protein-43 (TDP-43) cytoplasmic 
inclusions are pathological hallmarks of several neurodegenerative diseases, including 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).  
Furthermore, TDP-43 mutations have been identified in both familial and sporadic forms 
of ALS.  Despite evidence linking dysfunction of TDP-43 to neuronal cell death, it is 
currently unknown whether TDP-43-induced toxicity occurs via a gain of function or loss 
of function mechanism. In the present study, we initially examined the effects of either 
overexpression or knockdown of TDP-43 on neuronal survival in vitro.  Overt neuronal 
cell death was not induced by either experimental paradigm. However, it was noted that 
both endogenous and overexpressed TDP-43 partially localized to mitochondria within 
diverse neuronal and astrocytic cell types.  Furthermore, a significant decrease in the 
function of mitochondrial ETC Complex I occurred following TDP-43 knockdown in 
NSC34 motor neuron/neuroblastoma hybrid cells. Our data suggest a novel link between 




TDP-43 is an hnRNP protein that was first discovered because of its ability to 
bind the transactive response region of HIV-1, where it represses gene expression (Ou et 
al., 1995).  Since its discovery, TDP-43 has been consistently demonstrated to be 
involved at various levels of gene expression, such as modulation of exon splicing 
(Buratti et al., 2001; Mercado et al., 2005; Ayala et al., 2008), modulation of gene 
expression through direct DNA and RNA binding (Ayala et al., 2005; Acharya and 
Reddi, 2006; Strong et al., 2007), and modulation of gene expression through 
stabilization of mRNA (reviewed in Chen-Plotkin et al., 2010).  In addition to direct 
interactions with RNA and DNA, TDP-43 also participates in protein-protein interactions 
through its C-terminal glycine-rich domain, notably with other hnRNP proteins involved 
in alternative splicing (Buratti et al., 2005; D’Ambrogio et al., 2009).  Although 
predominantly located in the nucleus, TDP-43 can be exported via its nuclear export 
signal (NES) to perform functions in the cytoplasm (Ayala et al., 2008; Winton et al., 
2008). 
Perhaps the most notable recent finding in regards to ALS pathology is that 
cytoplasmic ubiquitin-positive inclusions containing TDP-43 are consistently found in 
both sporadic and most familial forms of the disease (Arai et al., 2006; Neumann et al., 
2006; Davidson et al., 2007; Dickson et al., 2007; Brandmeir et al., 2008).  The 
significance of this discovery is underscored in that other histopathological findings in 
familial and sporadic forms of ALS are seemingly heterogeneous.  As such, evaluation of 
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the mechanism behind dysregulation and aggregation of TDP-43 has become a recent 
focus in ALS research. 
In addition to TDP-43 pathological findings, mutations in TDP-43 are also found 
in a subset of familial ALS cases.  The Ala-315-Thr (A315T) mutation in TDP-43 was 
initially discovered in a genetic screen of families exhibiting an autosomal dominant 
inheritance of ALS (Glitcho et al., 2008).  This residue is highly conserved within the 
glycine-rich domain, indicative of its functional importance.  ALS patients harboring the 
A315T TDP-43 mutation are affected by significant TDP-43 histopathology concomitant 
with extensive motor neuron loss in the spinal cord.  Although it is accepted that 
mutations in TDP-43 are involved in some forms of ALS, the direct toxic effects of  
TDP-43 mutations to neurons remain to be established. 
Despite the preponderance of evidence demonstrating that TDP-43 inclusions are 
an almost universal finding in the pathophysiology of ALS and FTLD, the processes 
behind TDP-43 mediated toxicity remain to be fully elucidated. Studies into the effects 
and mechanisms of TDP-43 aggregation have produced varying results, yet the one factor 
that remains consistent is that increased TDP-43 cytoplasmic localization is 
commensurate with a marked loss of nuclear TDP-43.   A central challenge in 
understanding how TDP-43 defects mediate neuronal cell death is ascertaining whether 
toxicity occurs from gain of function (GOF) effects due to aberrant cytoplasmic 
localization or loss of function (LOF) effects due to a deficiency in nuclear TDP-43 
functions.  Indeed, current literature supports both options, and a dichotomy remains on 
the answer to this question. 
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In the present study, we used the NSC-34 motor neuron/neuroblastoma hybrid cell 
line to evaluate the effects of overexpressing GFP-tagged wild-type (WT) or A315T 
mutant TDP-43 in this system.  Additionally, we used siRNA to effectively knock-down 
expression of endogenous TDP-43.  Consistent with previous findings, we noted that 
exogenous GFP-TDP-43 had a predominantly nuclear localization along with noticeable 
cytoplasmic staining, using both WT and A315T constructs.  However, neither 
overexpression of WT or A315T TDP-43 or knock-down of endogenous TDP-43 had 
overt toxic effects to NSC-34 cells.  We were able to demonstrate that GFP-tagged WT 
and A315T TDP-43, as well as endogenous TDP-43, localized to the mitochondria in 
various cell types.  Furthermore, depletion of endogenous TDP-43 caused a significant 
decrease in mitochondrial Complex I activity.  Collectively, these findings indicate a 
potential novel function of TDP-43 in facilitating mitochondrial function and physiology. 
 3.3 Materials and Methods 
3.3.1 Materials 
 
The monoclonal antibody to TDP-43 was obtained from ProteinTech (Chicago, 
IL, USA). The monoclonal antibody to OPA1 (residues 708–830) was obtained from BD 
Biosciences (San Diego, CA, USA).  Ethacrynic acid and primary antibody against -
tubulin, were purchased from Sigma-Aldrich (St. Louis, MO, USA). The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell viability assay, 
Geneticin (G418) and Lipofectamine 2000 were obtained from Invitrogen (Carlsbad, CA, 
USA). Anti-glyceraldehyde 3-phosphate dehydrogenase (Anti-GAPDH) was from 
Abcam (Cambridge, MA, USA). Horseradish peroxidase-linked secondary antibodies and 
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reagents for enhanced chemiluminescence were from GE Healthcare (Pittsburgh, PA, 
USA).  The monoclonal β-tubulin antibody was from Sigma-Aldrich (St. Louis, MO, 
USA). A CY3-conjugated secondary antibody for immunofluorescence was from Jackson 
Immunoresearch Laboratories (West Grove, PA, USA).  DharmaFECT Transfection Kit, 
smart pool siRNA against mouse TDP-43, and non-target siRNA were from 
Thermoscientific Pierce Biotechnology (Rockford, IL, USA). Optimem and Dulbecco's 
modified Eagle's medium were purchased from Gibco (Carlsbad, CA, USA). NSC34 
cells were kindly provided by Dr. Neil Cashman (University of British Columbia).  GFP-
tagged wild type and A315T mutant TDP-43 constructs were kindly provided by Dr. Jane 
Wu at Northwestern University. 
3.3.2 Cell Culture 
 
NSC-34 cells were plated at a concentration of 250,000 cells per well in a tissue 
culture treated 6-well culture vessel and maintained in high-glucose DMEM, 10% FBS, 
1% pen-strep. Subsequent to initiation of the siRNA protocol, the media was changed to 
antibiotic free media per manufacturer’s recommendations.  In general, treatments were 
initiated 48 hours after plating and transfections were initiated 24 hours after plating. 
3.3.3 Transfection procedure 
 
Transfections were carried out in NSC-34 cells 24 hours post-plating following 
standard Lipofectamine 2000 protocol.  Cells were transfected with 5 g GFP-tagged 
wild type TDP-43, A315T TDP-43 or GFP control vectors as indicated in the results 
section.  In general, expression was carried out for 48 or 72 hours, as indicated in the 
results section.  
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3.3.4 Cell lysis and immunoblotting 
 
After treatment as described in the Results section, cells were washed once in 
1 mL ice-cold phosphate-buffered saline (PBS) (pH 7.4). Cells were incubated for 10 min 
on ice in lysis buffer (150–200 μl per 35-mm well) prepared as described previously 
(Loucks et al., 2006). The cells were then harvested by scraping, and cell debris were 
removed by centrifugation at 6000 g for 2 min. Protein concentration was determined 
using BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) with final 
absorbance of samples measured by a microplate spectrophotometer (BioTek 
PowerWave XS2, Winooski, VT, USA). Whole cell lysates were subjected to SDS-
PAGE through 7.5% polyacrylamide gels. Resolved proteins were transferred to PVDF 
membranes and processed for immunoblot analysis as previously described (Loucks et 




After treatment as described in the Results section, cells were fixed for 1 h at 
room temperature in 4% paraformaldehyde followed by permeabilization and blocking in 
0.2% Triton X-100 and 5% BSA in 1X PBS (pH 7.4) for 1 hour.  Cells were incubated in  
DAPI diluted in 2% BSA and 0.2% Triton X-100 in PBS for 30 minutes. Cells were then 
washed five times in 1X PBS followed by addition of anti-quench (5 mg/ml p-





3.3.6 Cell Fractionation 
 
Cells were treated as indicated in the results section. Media was aspirated, and 
cells were washed once with 1X ice-cold phosphate-buffered saline (PBS), pH 7.4. One 
ml of cytosolic buffer provided in the kit was diluted 1:5 in ddH2O, with added protease 
inhibitor cocktail (supplied in kit), and 1 mM dithiothreitol (DTT) as per the 
manufacturer's recommendations. A 100-μL aliquot of the cytosolic buffer was added per 
well and incubated on ice for 20 min, at which point cells were harvested and 
homogenized with 60-80 passes of a Dounce pestle. Effective homogenization at this step 
was confirmed microscopically. A whole cell lysate sample was collected at this point 
and added to wahl lysis buffer.  Samples were then spun down at 720 g for 10 min at 4°C 
two times, with the supernatant removed and placed in a fresh tube each time. The 
supernatant was transferred to a fresh tube and spun tube down at 10 000 g for 30 min at 
4°C to collect the mitochondrial pellet, which was resuspended in 100 μL of 
mitochondrial buffer (provided in the kit) with protease inhibitor cocktail and 1 mM 
dithiothreitol as per the manufacturer's recommendations. The remaining cytosolic 
supernatant was transferred to a fresh tube. Samples were immediately used for further 
experiments or stored at -20 °C. 
3.3.7 MTT viability assay 
 
After treatment as indicated in the Results section, NSC-34 cells were incubated 
with 100 μL of 12 mM MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) for 4 h at 37°C, 10% CO2. 2 ml of dimethyl sulfoxide 
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 siRNA mediated knockdown of TDP-43 
 
NSC-34 cells were transfected with either the SMARTPOOL
®
 (Thermo 
Scientific, Pittsburgh, PA, USA) siRNA against mouse TDP-43 or the non-target siRNA 
pool using the DharamaFECT transfection protocol. Briefly, 50-100 nM of indicated 
siRNA per well was incubated with 5 μL of DharmaFECT transfection reagent separately 
with serum-free medium for 5 min at ~25°C. siRNA and DharmaFECT in serum-free 
medium were mixed and incubated at ~25°C for 20 min. The mixture of 
siRNA/DharmaFECT was then added to the cells and incubated for 24 h at 37°C and at 
10% CO2 before subsequent experiments were completed. 
3.3.9 Oroboros 
 
High resolution respirometry was carried out using Oxygraph 2-k, (O2k) 
Oroboros Instrument as described in Hughey et al. (2011) and Kane et al. (2011).  
Briefly, following 72 hour siRNA construct expression, cells were trypsinized, and cell 
counts were obtained.  250,000 cells in MiR05 were used per each 2 ml oxygraph 
chamber and resuspended in MiR05 media.  Using a 10 μL Hamilton microsyringe, cells 
were permeabilized using titrations of 0.3 μL 10mM digitionin until baseline respiration 
was achieved.  Using 25 μL Hamilton microsyringe, 5 mM pyruvate, 2 mM malate, and 
10 mM glutamate (final concentrations) were injected into each system to establish leak 
state respiration.  2 μL injections of 0.5 M ADP were titrated until respiration began to 
decrease in control samples.  6 μL Succinate, 5 μL cytochrome c, 5 μL oligomycin, and 1 
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μL FCCP were titrated at 1 M, 4 mM, 4 mg/ml, and 1 mM stock concentrations, 
respectively. 
3.4 Results 
3.4.1 Overexpression of WT or A315T mutant TDP-43 is not overtly toxic to NSC-34 
motor neuronal cells. 
 
In an effort to clarify the discrepancy between TDP-43 loss-of-function or gain-
of-function theories, we sought to delineate any possible gain of function toxic effects of 
TDP-43 overexpression. We transiently expressed GFP tagged-wild-type (WT) and 
A315T mutant TDP-43 in NSC-34 motor neuron/neuroblastoma hybrid cells.  After 24 
and 48 hours of expression, cell viability of GFP-expressing cells was established by 
assessing nuclear morphology for signs of cell death.  As dividing cells display somewhat 
condensed nuclei, only those cells with clearly fragmented nuclei were counted as non-
viable.  There was no difference in toxicity observed in either A315T mutant or WT 
TDP-43 as compared to YFP-control transfected NSC-34 cells.  GFP-tagged A315T and 
WT TDP-43 both had a principally nuclear localization and diffuse cytoplasmic staining, 
with somewhat punctate foci observed in both transfections (Fig 3.4.1A). 
Although there was no overt morphologic toxicity observed due to overexpression 
of either form of TDP-43, it remained to be determined if overexpression rendered NSC-
34 cells sensitive to cell stressors.  Previous studies have established a correlation 
between proteasome inhibition and TDP-43 aggregation (van Eersel, et al., 2011). 
Furthermore, it has been found that conditional knock-out of proteosome subunit Rpt3 in 
mice resulted in ALS phenotype and ALS-like TDP-43 pathophysiology (Tashiro et al., 
2012).  As such, we sought to determine if overexpression of GFP-tagged WT or A315T 
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TDP-43 rendered NSC-34 cells more susceptible to proteasomal inhibition. After 48 
hours of expression of GFP-control, WT or A315T TDP-43, NSC-34 cells were 
subsequently treated with 1 or 10 M of the proteasome inhibitor MG132 for 48 hours.  
Again, toxic effects were analyzed by assessing the nuclear morphology of transfected 
cells under the various treatment conditions.  There was not a substantial increase in cell 
death observed with either GFP-tagged WT or A315T TDP-43 when treated with MG132 
(as compared to GFP control vector), although a slight trend in increased cell death was 





Fig. 3.4.1 - Overexpression of WT or A315T mutant TDP-43 is not overtly toxic to 
NSC-34 motor neuronal cells.  (A) NSC-34 cells were transfected for 24 and 48 hours 
with GFP-tagged WT TDP 43, A315T TDP 43 and YFP control vectors.  Nuclei are 
stained with DAPI.  Exogenous vectors expressing GFP are shown to localize to the 
nucleus (blue) and cytoplasm.  GFP-positive cells were evaluated for cell death by 
assessing nuclear morphology, as described in the results section.  Values are given as a 
percent of total transfected (GFP-positive) cells that contain fragmented nuclei. There 
was no difference in toxicity observed in either A315T mutant or WT TDP-43 as 
compared to YFP-control vector.  (B) NSC-34 cells were treated with 1 or 10 M of the 
proteasome inhibitor MG132 for 48 hours after 48 hours expression of GFP-control, WT 
or A315T TDP-43.  Again, toxic effects were analyzed by assessing cell morphology of 
transfected cells under the various treatment conditions.  There was not a substantial 
increase in cell death observed with either GFP-tagged WT or A315T TDP-43 when 
treated with MG132 (as compared to GFP-tagged control vector), although a slight trend 




3.4.2 Depletion of cellular TDP-43 is not toxic to NSC-43 cells 
 
Based on literature describing that TDP-43 related neuronal cell death is a result 
of a loss-of-function of TDP-43, we sought to determine the effects of knock-down of 
TDP-43 in NSC-34 cells.  Cells were transfected with either siRNA to TDP-43 or non-
target siRNA for 72 hours.  Efficacy of transfection and subsequent knockdown of TDP-
43 was determined by western blotting, and revealed a marked 60% decrease in TDP-43 
protein levels using TDP-43 targeted siRNA, as compared to non-target siRNA and 
mock-transfected controls (transfection protocol carried out without the use of an siRNA 
construct) (Fig  3.4.2 A).  Importantly, noticeable knockdown of TDP-43 using the non-
targeted siRNA was not apparent, as compared to mock-transfected controls, indicating 
that knockdown using the TDP-43 targeted siRNA was not due to other effects of 
transfection (3.4.2 A). 
After establishing significant knockdown of TDP-43, an MTT cell viability assay 
was used to evaluate differences in cell survival between the different experimental 
conditions.  There was no significant difference in cell survival when comparing the 
TDP-43 siRNA transfection versus the non-target transfection.  Of note, a decrease in 
viability was apparent in both the TDP-43 siRNA and non-target siRNA, as compared to 
controls cells not exposed to any of the transfection conditions (non-transfected controls), 
indicating an inherent toxicity in the transfection procedure (3.4.2 B).  This is consistent 
with what was observed microscopically, as both transfected conditions had a decrease in 
the number of cells that remained attached after the transfection period, while control 




Fig. 3.4.2 - Depletion of cellular TDP-43 expression levels is not toxic to NSC-43 
cells.  NSC-34 cells were transfected with TDP-43 or non-target (NT) siRNA for 72 
hours. (A)  Efficacy of transfection was determined by western blotting.  Relative TDP-
43 protein levels are indicated relative to Actin control amounts. TDP-43 targeted siRNA 
caused a 60% decrease in TDP-43 protein levels (compared to non-target siRNA and 
mock-transfected controls). (B)  Relative survival as determine by MTT cell viability 
assay.  No significant difference in cell survival was observed when comparing the TDP-








 3.4.3 Endogenous and GFP-tagged TDP-43 partially localize to mitochondria 
 
In order to better establish the effects of TDP-43 in NSC-34 cells, we transfected 
GFP-tagged WT and A315T TDP-43 and performed cell fractionation into mitochondrial 
and cytosolic fractions.  Interestingly, immunoblotting revealed the presence of 
endogenous TDP-43 in all cell fractions examined, including the mitochondrial fraction.  
Moreover, transfected GFP-tagged WT and A315T TDP-43 also localized to the 
mitochondrial fractions (Fig. 3.4.3 A). 
 In order to establish that TDP-43 localization to mitochondria is not a 
phenomenon of the NSC-34 cell line, we performed cell fractionation on several other 
neuronal cell lines as well as primary neuronal and non-neuronal cultures.  Interestingly, 
TDP-43 localization to the mitochondria occurred in all cell lines examined, specifically, 
HT22 hippocampal cell line as well as primary cerebellar granule neurons and primary 





Fig. 3.4.3 - Endogenous and GFP-tagged TDP-43 partially localize to mitochondria.  
(A)  NSC -34 cells were transfected with GFP-tagged WT and A315T TDP-43 and then 
subjected to cell fractionation.  Immunoblotting revealed the presence of endogenous 
TDP-43 (**) in all cell fractions examined, including the mitochondrial fraction.  GFP 
tagged WT and A315T TDP-43 (*) also localized to the mitochondrial fractions.  
Enrichment of mitochondrial and cytoplasmic fractions is confirmed by OPA1 and 
GAPDH. (WC=whole cell lysate; C=cytoplasmic fraction; M=mitochondrial fraction.  
(B)  Cell fractionation and immunoblotting of non-transfected HT22 hippocampal cell 
line and astrocyte and CGN primary neuronal cultures also demonstrated endogenous 
TDP-43 localization to the mitochondria.  Enrichment of mitochondrial fractions is 
confirmed by OPA1 in HT22 immunoblot and dicarboxylate carrier (DIC) in 





3.4.4 Knockdown of TDP-43 induces mitochondrial Complex I deficiency 
 
In an effort to delineate the possible function of TDP-43 mitochondrial 
localization, we performed high-resolution respirometry using the OROBOROS 
Oxygraph-2k (O2k) system.  NSC-34 cells were subjected to TDP-43 or non-target 
siRNA for 48 hours. After permeabilizing cells with digitionin, resting state (LEAK state) 
respiration was established in the presence of complex I substrates pyruvate, malate, and 
glutamate (PMG).  Oxygen consumption under non-transfected and TDP-43 or non-target 
(NT) siRNA conditions remained equally low under these conditions.  Upon initiation of 
oxidative phosphorylation (OXPHOS) through the addition of ADP, respiration was 
significantly less in TDP-43 siRNA treated cells as compared to non-transfected and NT 
siRNA treatments, indicating a defect in oxidative phosphorylation under these 
conditions.  Of note, although NT treated cells had a higher respiration with the addition 
of ADP, it was visibly lower than what was observed in non-transfected controls.  Again, 
this is likely due to the inherent toxicity from the transfection procedure.  A surprising 
finding was that upon addition of the Complex II substrate, succinate, respiration in TDP-
43 siRNA treated cells returned to what is seen in control/NT conditions.  This is 
significant, as it effectively demonstrates that the observed OXPHOS deficiency can be 
overcome through bypassing Complex I.  Respiration measurements with the addition of 
Complex V inhibitor, oligomycin, and the uncoupler FCCP remained similar under all 
experimental conditions (Figure 3.4.4 A).  Statistical comparison of the respiration levels 
seen with addition of ADP, succinate and FCCP in all treatment conditions revealed a 
significant difference in Complex I function under TDP-43 siRNA conditions (Fig.3.4.4 
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B).  Of note, whole cell lysates from each experimental condition were analyzed by 
immunoblotting to confirm that efficient TDP-43 knockdown (approximately 60%) was 







                                                                  
*     **
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Fig. 3.4.4 - Knockdown of TDP-43 induces mitochondrial Complex I deficiency.    
NSC3-34 cells were subjected to TDP-43 or non-target (NT) siRNA for 48 hours and 
analyzed for respiration efficiency using the OROBOROS Oxygraph-2k (O2k) high-
resolution respirometer.  Results were analyzed as compared to non-transfected control 
cells. (A) Resting state (LEAK state) respiration is comparable in all experimental 
conditions.   Respiration is demonstrably less in TDP-43 siRNA treated cells as compared 
to non-transfected and NT siRNA treatments upon initiation of oxidative phosphorylation 
(OXPHOS) through the addition of ADP (*). Non-target siRNA treated cells display 
lower respiration than what is observed in non-transfected controls, indicating toxicity 
from the transfection procedure (*).  Respiration in all three experimental conditions 
returns to comparable levels upon the addition of the Complex II substrate succinate (**).  
Respiration measurements are equivalent in all three experimental conditions during the 
addition of Complex V inhibitor, oligomycin, and the uncoupler FCCP.  (B)  Statistical 
comparison of respiration levels seen with addition of ADP, succinate, and FCCP in all 
treatment conditions reveals a significant difference in respiration levels during ADP 
addition to TDP-43 siRNA treated cells, (but not with addition of succinate or FCCP), as 
compared to non-transfected controls. *p < 0.05 paired Student's t-test, n = 7, error bar 
indicates SEM.  Values shown are respiration levels of TDP-43 siRNA treated cells 





TDP-43 LOF and GOF models represent opposing ends on the spectrum of 
theories regarding the relationship between TDP-43 dysfunction and ALS/FTLD 
pathologies.  Indeed, abundant evidence is all but conclusive that an underlying cause of 
these neurodegenerative diseases consists of atypical events involving this protein.  
However, the list of known TDP-43 functions is substantial and certainly not exhaustive, 
which has proven to be an added challenge in discerning putative gain-of-function or 
loss-of-function effects of TDP-43 dysfunction.  Given these considerations, 
extrapolating the definitive mechanisms behind TDP-43 mediated neuronal cell death 
will undoubtedly be a complex process. 
In the present study, we used in vitro overexpression and siRNA knockdown 
methods to approximate gain-of-function and loss-of-function effects, respectively.  Each 
approach failed to elicit overt neuronal cell death or cause any morphological toxic 
effects. Overexpression data presented here were evaluated by assessing for apoptotic 
morphology in cells that were clearly expressing the GFP-tagged construct.  Although 
this approach was seemingly prone to observer bias, other more objective methods 
(including flow cytometric analysis and cell viability assays) did not yield substantially 
different results.  Furthermore, in order to account for transfection efficiency, visual 
assessment of each cell was necessary in order to consider only those cells that had been 
transfected.  In contrast, siRNA studies utilized the MTT cell viability assay to more 
broadly assess for cell survival in TDP-43 siRNA treated cultures.  Although we were 
able to substantially reduce TDP-43 expression levels (as evaluated by immunoblotting), 
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there was not considerable reduction in cell viability as a result of TDP-43 knockdown. 
Ultimately, despite multiple approaches and means of evaluating our data, we were not 
able to demonstrate TDP-43-mediated toxicity using these systems to model the effects of 
gain-of-function and loss-of-function.   
The preceding findings, although seemingly inconclusive, are commensurate with 
the dichotomy in currently held theories surrounding the effects of TDP-43 loss-of-
function or gain-of-function.  Therefore, we considered this question in the broader 
context of mechanisms known to be involved in neurodegeneration and sought to 
evaluate if TDP-43 has any interaction with mitochondrial function.  Surprisingly, it was 
noted that both endogenous and GFP-tagged TDP-43 (wild type or mutant) partially 
localized to mitochondrial fractions.  This finding is significant because it established a 
previously unreported physical association between TDP-43 and the mitochondria, even 
under basal conditions.   
To further characterize these findings, we examined mitochondrial function 
during conditions of decreased TDP-43 levels using high-resolution respirometry.  
Remarkably, TDP-43 siRNA treated cells demonstrated a deficit in mitochondrial 
oxidative phosphorylation.  Further evaluation during these studies revealed that 
mitochondrial respiration returned to control levels when the system was able to bypass 
ETC Complex I by using by utilizing substrates (succinate) that are used by Complex II.  
Collectively, these findings demonstrate that significant mitochondrial complex I deficits 
occur upon depletion of cellular TDP-43 levels.  These data are important in that they 
establish a relationship between TDP-43 and mitochondrial function.  Until very recently, 
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this association had not been reported.  Since we made this discovery, other reports have 
substantiated our findings.  Transfected wild type, mutant, and TDP-43 C-terminal 
fragment localization to mitochondria has been validated through several studies utilizing 
cell fractionation, immunoblotting, and immunostaining (Hong et al., 2012; Wang et al., 
2013).  Importantly, Wang et al. (2013) was also able to establish that TDP-43 
suppression in primary motor neurons had a deleterious effect on mitochondrial dynamics 
and function. Alternatively, overexpression studies have demonstrated deficits in 
mitochondrial morphology, membrane potential, and, activity of mitochondrial ETC 
Complex I (Hong et al., 2012; Lu et al., 2012; Wang et al., 2012).    These overexpression 
studies are interesting when juxtaposed with knockdown studies, and indicate that 
mitochondrial health and function is susceptible to a fragile balance of TDP-43 levels.    
 TDP-43 functions are largely comprised of modulating gene expression through 
direct DNA and RNA binding.  We propose that TDP-43 may be involved in regulation 
of mitochondrially encoded ETC components, and that disruptions in TDP-43 function 
result in a disturbance in the production of these essential proteins.  Importantly, 
mitochondrial complex I proteins comprise the largest portion of protein coding genes 
within the mitochondrial genome.  This is in accord with our discovery that TDP-43 
deficiency results specifically in a deficit in the function of complex I.   
 We propose a model in which one of the endogenous functions of TDP-43 is to 
modulate expression of mitochondrially encoded ETC components.  It is well established 
that ALS-associated cellular conditions, such as oxidative stress, can result in impaired 
mitochondrial membrane potential and disruption of mitochondrial respiration and 
 
112 
dynamics.  We suggest that during these scenarios, nuclear export of TDP-43 is increased 
in order to facilitate increased regulation of mitochondrially encoded ETC components in 
an effort to offset potential damage incurred to mitochondrial components.  In extreme 
circumstances, such as what is observed during neurodegeneration, nuclear export of 
TDP-43 is increased to levels that overwhelm cytoplasmic protein trafficking systems.  
Subsequently, TDP-43 aggregates form and become ubiquitinated by proteosome 
machinery in an effort to combat these effects.  Future studies, including quantification of 
mitochondrially encoded Complex I mRNA levels, will be necessary to appropriately test 








Chapter Four:  TDP-43 nuclear export is partially mediated by mitochondrial 
glutathione levels and c-Jun N –Terminal Kinase 
4.1 Abstract 
TAR DNA-binding protein-43 (TDP-43) cytoplasmic inclusions are a consistent 
pathological finding in several neurodegenerative diseases, including amyotrophic lateral 
sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).  Furthermore, mutations 
in TDP-43 are identified in both familial and sporadic forms of ALS, which underscores 
the significance of this protein in ALS etiology.  Despite the preponderance of evidence 
linking TDP-43 dysfunction to neuronal cell death, little insight has been given into the 
regulation of TDP-43 nuclear export and cytoplasmic localization.  In the present study, 
we report that TDP-43 nuclear export is enhanced by reductions in cellular glutathione 
(GSH) levels.  This effect is inhibited by overexpression of the mitochondrial GSH 
transporter, the 2-oxoglutarate carrier (OGC), which specifically increases the 
mitochondrial GSH pool.  In addition, inhibition of c-Jun N-terminal kinase (JNK) but 
not p38 MAP kinase effectively ameliorates EA-induced TDP-43 nuclear export.  Our 
data offers insight into regulatory mechanism of TDP-43 cellular distribution and further 
emphasize a relationship between mitochondrial physiology, TDP-43 dysfunction, and 





TDP-43 dysfunction is a hallmark of several neurodegenerative diseases, such as, 
ALS and FTLD (Neumann et al. 2006; Cairns et al., 2007).  It is classified in the hnRNP 
family of proteins and is involved various aspects of gene expression through direct 
binding of RNA and DNA.  Under normal conditions, TDP-43 is predominantly located 
in the nucleus, but is continuously imported and exported to perform various nuclear and 
cytoplasmic functions (Ayala et al., 2008; Winton et al., 2008). However, TDP-43 is 
shown to form cytoplasmic ubiquitin-positive inclusions in brain and spinal cord motor 
neurons of ALS patients (Neumann et al., 2006).  Furthermore, it has been shown that 
these cytoplasmic aggregates contained hyperphosphorylated and cleaved TDP-43 
fragments (Arai et al., 2006; Neumann et al., 2006 Cairns et al., 2007; Giordana et al., 
2010).  Importantly, increased cytoplasmic distribution of TDP-43 occurs in conjunction 
with decreased nuclear TDP-43 levels, which is indicative of TDP-43 loss of function in 
the nucleus.  Despite the prevalence of these findings in disease processes, the 
mechanisms involved in TDP-43 cellular distribution are not well established.   
Previously, we described that TDP-43 consistently localizes partially to 
mitochondria in diverse neuronal cell types, implying a potential link between TDP-43 
proteinopathy and mitochondrial-dependent neuronal cell death.   In addition, siRNA-
mediated TDP-43 depletion was associated with a deficit in mitochondrial ETC complex 
I, establishing a correlation between TDP-43 function and mitochondrial physiology. In 
the present study, we report that TDP-43 nuclear export is enhanced by specific 
reductions in mitochondrial GSH levels in NSC-43 cells.  This effect is inhibited by 
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stable overexpression of the mitochondrial GSH transporter, OGC, which specifically 
increases the mitochondrial GSH pool.  Furthermore, inhibition of c-Jun N-terminal 
kinase (JNK) but not p38 MAP kinase effectively ameliorates EA- induced TDP-43 
nuclear export.  Our data suggest a novel method of regulating TDP-43 cellular 
distribution and further highlight a relationship between mitochondrial physiology, TDP-
43 dysfunction, and neuronal cell death. 
 
4.3 Materials and Methods 
4.3.1 Materials 
 
The monoclonal antibody to TDP-43 was obtained from ProteinTech (Chicago,IL, 
USA). The monoclonal antibody to OPA1 (residues 708–830) was obtained from BD 
Biosciences (San Diego, CA, USA). Mitochondrial/cytosolic fractionation kit was from 
Biovision (Mountain View, CA, USA), ethacrynic acid, -tubulin, and GSH 
monoethylester were purchased from Sigma-Aldrich (St. Louis, MO, USA)., Geneticin 
(G418) was obtained from Invitrogen (Carlsbad, CA, USA). The GSH assay was 
purchased from Oxford Biomedical (Rochester Hills, MI, USA). The 
mitochondrial/cytosolic fractionation kit was from Biovision (Mountain View, CA, 
USA). Antibody against cytochrome c oxidase IV (Cox-IV) was purchased from Cell 
Signaling (Beverly, MA, USA). Anti-glyceraldehyde 3-phosphate dehydrogenase (Anti-
GAPDH) was purchased from Abcam (Cambridge, MA, USA). Secondary antibodies for 
immunoblotting and reagents for enhanced chemiluminescence were obtained from GE 
Life Sciences (Piscataway, NJ, USA). DharmaFECT Transfection Kit, smart pool siRNA 
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against mouse TDP-43, and non-target siRNA were from Thermoscientific Pierce 
Biotechnology (Rockford, IL, USA). Optimem and Dulbecco's modified Eagle's medium 
were obtained from Gibco (Carlsbad, CA, USA). The V5-OGC plasmid used to create 
stably expressing NSC-34 cells was a generous gift from Dr. Larry Lash (Wayne State 
University). NSC34 cells were kindly provided by Dr. Neil Cashman (University of 
British Columbia). 
4.3.2 Cell Culture 
 
NSC-34 cells were plated at a concentration of 250,000 cells per well in a tissue 
culture treated 6-well culture vessel and maintained in high-glucose DMEM, 10% FBS, 
1% pen-strep.  OGC-overexpressing NSC-34 cells were established as described in 
Wilkins et al. (2014) and maintained through addition of 500 μg/mL of G418 in NSC-34 
media. 
4.3.4 Cell lysis and immunoblotting 
 
After treatment as described in the Results section, cells were washed once in 
1 mL ice-cold phosphate-buffered saline (PBS) (pH 7.4). Cells were incubated for 10 min 
on ice in lysis buffer (150–200 μl per 35-mm well) prepared as described previously 
(Loucks et al., 2006). The cells were then harvested by scraping and cell debris were 
removed by centrifugation at 6000 g for 2 min. Protein concentration was determined 
using BCA protein assay kit (Thermo Scientific, Rockford, IL, USA) with final 
absorbance of samples measured by a microplate spectrophotometer (BioTek 
PowerWave XS2, Winooski, VT, USA). Whole cell lysates were subjected to SDS-
PAGE through 7.5% polyacrylamide gels. Resolved proteins were transferred to PVDF 
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membranes and processed for immunoblot analysis as previously described (Loucks et 




After treatment as described in the Results section, cells were fixed for 1 h at 
room temperature in 4% paraformaldehyde followed by permeabilization and blocking in 
0.2% Triton X-100 and 5% BSA in 1X PBS (pH 7.4) for one hour.  Cells were incubated 
overnight in TDP-43 primary antibody and DAPI diluted in 2% BSA and 0.2% Triton X-
100 in PBS. Cells were then washed five times in 1X PBS followed by a 1 hour 
incubation in FITC-conjugated secondary antibody diluted in 2% BSA and 0.2% Triton-
X 100 in PBS.  Subsequent to washing five times in 1X PBS, cells were placed in anti-
quench (5 mg/ml p-phenylenediamine in 1X PBS).   Increased cytoplasmic TDP-43 
levels were indicated by cells which maintained significant FITC TDP-43 fluorescence 
when control cytoplasmic FITC levels were decreased to undetectable amounts.   
4.3.6 Cell Fractionation 
 
Cells were treated as indicated in the results section. Media was aspirated and 
cells were washed once with 1X ice-cold phosphate-buffered saline (PBS), pH 7.4. One 
ml of cytosolic buffer provided in the kit was diluted 1 : 5 in ddH2O, with added protease 
inhibitor cocktail and 1 mM dithiothreitol as per the manufacturer's recommendations. A 
100-μL aliquot of the cytosolic buffer was added per well and incubated on ice for 
20 min, at which point cells were harvested and homogenized with 60-80 passes of a 
Dounce pestle. Effective homogenization at this step was confirmed microscopically. A 
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whole cell lysate sample was collected at this point and added to wahl lysis buffer.  
Samples were then spun down at 720 g for 10 min at 4°C two times, with the supernatant 
removed and placed in a fresh tube each time. The supernatant was transferred to a fresh 
tube and spun tube down at 10 000 g for 30 min at 4°C to collect the mitochondrial pellet, 
which was resuspended in 100 μL of mitochondrial buffer (provided in the kit) with 
protease inhibitor cocktail and 1 mM dithiothreitol as per the manufacturer's 
recommendations. The remaining cytosolic supernatant was transferred to a fresh tube.. 
Samples were immediately used for further experiments or frozen down at -20 C. 
4.3.7 Glutathione Assay 
 
Glutathione levels [reduced GSH + oxidized glutathione (GSSG)] were measured 
using an assay kit (DTNB) from Oxford Biomedical, following the manufacturer's 
protocol. All glutathione measurements were normalized to protein concentration and 
performed on fresh lysates. 
 
4.4 Results 
4.4.1 Depletion of cellular GSH levels induces nuclear export of TDP-43 
 
 In an effort to establish possible triggers of TDP-43 nuclear export, we evaluated 
the effects of mitochondrial oxidative stress on the cellular distribution of TDP-43 in 
NSC-34 cells.  Specifically, EA was used to deplete cellular GSH levels.  Cells were 
exposed to 50 M EA for 4 hours and subsequently stained for TDP-43.  Microscopic 
imaging revealed that TDP-43 has a predominantly nuclear localization in control 
conditions.  This is in accord with many studies that report TDP-43 exists primarily in the 
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nucleus.  Upon EA treatment, TDP-43 begins to adopt a cytoplasmic localization along 
with a decrease in nuclear presence.  To confirm that these observations are the result of 
EA effects on GSH levels, EA treatment was performed subsequent to 48 hour 
glutathione monoethylester (GSH-MEE) supplementation in order to restore cellular 
GSH levels.  These studies reveal that EA-induced TDP-43 nuclear export is prevented 
upon restoration of GSH levels (Fig. 4.4.1 A).  These findings are in accord with what 
has been recently reported by Iguchi et al. (2012). 
 We previously established that mitochondrial GSH levels are tightly coupled to 
oxidative stress induced neuronal cell death (Wilkins et al., 2013).  In order to establish 
the relevance of that paradigm to our present findings, we measured GSH levels in 
cellular fractions of NSC-34 cells exposed to GSH-MEE.  Interestingly, we reveal that 
that treatment of NSC-34 cells with GSH-MEE selectively increases mitochondrial GSH 
levels to well over that of non-treated conditions (Fig. 4.4.1 B) (Wilkins et al., 2014).  
These data suggest that depletion of mitochondrial GSH levels specifically has an effect 







Fig. 4.4.1 - Depletion of cellular GSH levels induces nuclear export of TDP-43.  (A)  
NSC34 cells were exposed to 50 M ethacrynic acid (EA) for 4 hours and subsequently 
stained for TDP-43 (green).  Nuclei are stained with DAPI (blue) TDP-43 has a 
predominantly nuclear localization in control conditions.  EA treatment induces nuclear 
export of TDP-43 along with an increase in cytoplasmic localization (indicated by 
arrows).  Pre-treatment with GSH monoethylester (GSH-MEE) prevents redistribution of 
TDP-43 (n=3 independent experiments).  (B)  Quantification of GSH levels indicates that 
treatment of NSC-34 cells with GSH-MEE selectively increases mitochondrial GSH 
levels.  Mitochondrial and cytosolic enrichment in cell fractions are indicated by COX-IV 
and GAPDH, respectively. **p < 0.01 versus control via an unpaired Student's t-test 
n = 7, error bar indicates SEM (as published in Wilkins et al., 2014).   
Acknowledgments are given to Heather M. Wilkins, PhD and Samantha Brock for their 




4.4.2 Stable expression of the mitochondrial OGC carrier specifically increases 
mitochondrial GSH levels. 
 
To better characterize the role of mitochondrial GSH in nuclear export of TDP-
43, we utilized an NSC-34 cell line established in our lab that stably expresses the 
mitochondrial inner membrane transporter OGC.  We recently reported that OGC is 
responsible for mitochondrial uptake of GSH via direct interactions with BCL2 in 
neurons (Wilkins et al., 2014).  These studies reveal that NSC-34 cells that stably 
overexpress this carrier have a marked and specific increase in mitochondrial GSH levels 
over that of control NSC-34 cells (Fig. 4.4.2 A).  In the context of EA depletion, it was 
also determined that these cells maintain mitochondrial GSH levels well above that of 
control cells during EA treatment, while cytosolic GSH levels remained similarly reduced 





Fig 4.4.2 - Stable expression of the mitochondrial 2-oxoglutarate effectively 
increases mitochondrial GSH levels.  (A) Cell fractionation and subsequent 
measurement of GSH levels in two different NSC-34 cell lines stably overexpressing the 
mitochondrial 2-oxoglutyrate carrier (OGC3, OGC6) demonstrate a significant increase 
in mitochondrial GSH levels over that of WT NSC-34 cells.  Enrichment of 
mitochondrial fraction is indicated by COX IV immunoblot. Mitochondrial data are 
represented as a percentage of WT mitochondrial GSH measurements.  *p < 0.05, 
**p < 0.01, unpaired Student's t-test, n=7 independent experiments, error bars indicate 
SEM. Cytosolic data are represented as a percentage of WT cytosolic GSH 
measurements. n=7 independent experiments, error bars indicate SEM.  (B) OGC3 cell 
line maintains mitochondrial GSH levels above that of control cells.  Data are represented 
as a percentage of WT control mitochondrial GSH measurements.  Cytosolic GSH levels 
remain similar between all cell types. Data are represented as a percentage of WT control 
cytosolic GSH levels. *p < 0.05, n=3 independent experiments, error bars indicate SEM. 
(As published by Wilkins et al., 2014). 
Acknowledgments are given to Heather M. Wilkins, PhD and Samantha Brock for their 





4.4.3 Stable overexpression of the mitochondrial OGC carrier prevents nuclear export 
of TDP-43. 
 
Mitochondrial GSH levels were effectively sustained during EA treatment in 
OGC overexpressing NSC-34 cells.  In contrast, cytosolic GSH levels decreased to that 
of WT cells.  Thus, it can be said that the OGC cell line, when challenged with EA, 
experiences a decrease in cellular GSH levels while maintaining mitochondrial GSH 
levels.   In consideration of this, we further investigated TDP-43 cellular distribution 
under this experimental paradigm.   Under control conditions, WT and OGC 
overexpressing cells both display TDP-43 localization to the nucleus, with a slight 
cytoplasmic presence.  However, upon treatment with EA, WT cells develop an increase 
in TDP-43 cytoplasmic distribution.  This is in stark contrast to the OGC cells, which 
maintain a nuclear TDP-43 distribution (Fig. 4.4.3 A).  Quantification of the number of 
cells displaying a marked cytoplasmic presence of TDP-43 reveals that OGC 
overexpression essentially prevents the redistribution of TDP-43 induced by EA in WT 
cells (Fig. 4.4.3 B).  These data further indicate that specific decreases in mitochondrial 





Fig. 4.4.3 - Stable overexpression of the mitochondrial 2-oxoglutarate carrier 
prevents nuclear export of TDP-43.  (A) WT and OGC overexpressing cells were 
treated with 70 M EA for 4 hours followed by staining and imaging.  TDP-43 is 
indicated in green and nuclei are indicated in blue (DAPI).  Both cell lines display TDP-
43 localization to the nucleus and a slight cytoplasmic presence.  Upon treatment with 
EA the WT cell line develops an increase in TDP-43 cytoplasmic distribution, as 
indicated by arrows, while the OGC cell line maintains nuclear TDP-43 levels.  (B)  
Quantification of the number of cells displaying an increase in cytoplasmic TDP-43 
levels.  EA acid treatment causes a significant increase in cytoplasmic levels of TDP-43 
in WT cells, as compared to non-treated WT cells. OGC6 cytoplasmic levels during EA 
treatment are not significantly different than control non-treated OGC6 cells.  
***p<0.001, NS = not significant via a one-way ANOVA with post hoc Tukey's test, 




4.4.4 Nuclear export of TDP-43 is ameliorated by inhibition of JNK but not p38 MAP 
kinase. 
 
It is accepted that JNK and p38 MAP kinase pathways are major contributors to 
cell stress responses during oxidative stress-induced apoptosis (Davis, 2000).  As such, 
we examined the effects of inhibiting these pathways during EA induced mitochondrial 
oxidative stress conditions.  WT NSC-34 cells were exposed to a 1 hour pre-treatment 
with either a JNK inhibitor (SP600125) or a p38 MAP kinase inhibitor (SB203580), 
followed by a 4 hour EA treatment and analyzed for TDP-43 cytoplasmic localization.   
Interestingly, pretreatment with the JNK inhibitor significantly attenuates EA induced 
TDP-43 nuclear export.  In contrast, inhibition of p38 MAP kinase does not seem to have 
any effect on TDP-43 nuclear export (Fig.4.4.4 A-B). These data indicate that oxidative 
stress-induced cell signaling via JNK is involved in TDP-43 cellular distribution induced 






Fig 4.4.4 - Nuclear export of TDP-43 is ameliorated by inhibition of JNK but not 
p38 MAP kinase.  Prior to EA treatment, WT NSC-34 cells were pre-treated for 1 hour 
with JNK inhibitor (SP600125) or p38 MAP kinase inhibitor (SB203580) and analyzed 
for TDP-43 cytoplasmic localization.  (A)  p38 MAP kinase (SB203580) does not have a 
significant effect on TDP-43 nuclear export. (B)  JNK inhibitor (SP600125) significantly 
attenuates EA induced TDP-43 nuclear export. *p < 0.05, paired Student's t-test,  







Protein aggregation is a common pathogenic mechanism in diverse 
neurodegenerative disorders.   TDP-43 cytoplasmic inclusions are pathological hallmarks 
of several neurodegenerative diseases, including ALS and FTLD.  Furthermore, TDP-43 
mutations have been identified in both familial and sporadic forms of ALS.  Under 
typical conditions, TDP-43 exists primarily in the nucleus, but is also continuously 
translocated between the nucleus and cytoplasm (Ayala et al., 2008; Winton et al., 2008).  
In our previous studies, we corroborated recent findings that TDP-43 partially localizes to 
the mitochondria in diverse neuronal cell types.  Despite these findings being established 
by other labs, there is still very little knowledge about the cell signaling that controls 
TDP-43 cellular distribution. 
Iguchi et al. recently reported that depletion of cellular GSH levels induces TDP-
43 cytoplasmic distribution (Iguchi et al., 2012).  These findings are some of the first to 
establish a possible mechanism that induces TDP-43 nuclear export. Moreover, 
unpublished data from our lab demonstrate that mitochondrial GSH levels are reduced in 
an ALS mouse model spinal cord tissue of transgenic ALS mice, which further 
substantiates the correlation between mitochondrial GSH levels and mitochondrial 
mediated neuronal cell death.  As such, we sought to delineate the role of mitochondrial 
GSH levels in TDP-43 nuclear export.   We report that TDP-43 nuclear export is 
enhanced by specific reductions in mitochondrial GSH levels in NSC-34 cells.  Similarly, 
redistribution of TDP-43 from the nucleus to the cytoplasm is induced by EA depletion of 
cellular GSH levels.  This effect is inhibited by stable overexpression of the 
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mitochondrial GSH transporter, OGC, which specifically increases the mitochondrial 
GSH pool.  Furthermore, inhibition of c-Jun N-terminal kinase (JNK) but not p38 MAP 
kinase effectively ameliorates EA induced TDP-43 nuclear export.  Our data suggest a 
novel mechanism of regulating TDP-43 cellular distribution and further highlights a 
relationship between mitochondrial physiology, TDP-43 dysfunction, and neuronal cell 
death.  These findings provide insight into possible triggers of TDP-43 nuclear export, 
and couples very specific redox events to the almost universal finding of increased TDP-
43 export to the cytoplasm in neurodegenerative diseases.  Further studies are needed to 
definitively establish a direct correlation between JNK signaling and TDP-43 cellular 
localization.  As such, we propose to ascertain the effects of overexpressing constitutively 
active JNK in these experimental paradigms, and hypothesize that this will induce 









Chapter Five: Conclusion 
Mitochondrial dysfunction is considered an integral component of cell death 
pathways involved in neurodegeneration.  As such, investigations into the origins and 
effects of these processes remain a fundamental component in determining possible 
therapeutic interventions.  Mitochondria can elicit cell death through release of 
cytochrome c and subsequent initiation of the apoptotic cascade, which is tightly coupled 
to disruptions in mitochondrial function as well as dysfunctions in the mitochondrial 
fission-fusion equilibrium.  Both conditions consistently occur in various 
neurodegenerative diseases; however, the cause and effect relationships remain 
controversial.  Thus, the purpose of the investigations presented here are to provide 
further insight into novel sources of disturbances in mitochondrial form and function, as 
well as correlate these events to other mechanisms that are coupled to the etiology of 
neurodegeneration. 
  5.1 Summary of major findings 
The major goal of chapter two was to further characterize an N-terminal cleavage 
of the mitochondrial fusion protein, OPA1.  Initial studies in primary neuronal cultures 
described this processing as being mediated indirectly by caspases under classical 
apoptotic conditions, resulting in a previously unreported truncation product.  Moreover, 
N-terminal cleavage of OPA1 occurs with concomitant fragmentation of the 
mitochondrial network and release of cytochrome c (Loucks et al., 2009).  As presented 
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in this thesis, it was subsequently discovered that an identical N-terminal OPA1 cleavage 
product occurred in neurons as a result of oxidative and nitrosative stress.  However, 
OPA1 processing under these conditions occurred in a caspase-independent manner.  Of 
note, an identical N-terminal cleavage product was also demonstrated to occur 
spontaneously in aged neural tissue (Gray et al., 2013).  Collectively, these findings 
establish that this N-terminal cleavage of OPA1 is coupled to mitochondrial dysfunction, 
and occurs in oxidative and nitrosative stress environments that are consistently linked to 
both aging the pathogenesis of neurodegenerative diseases. 
 Studies performed in chapters three and four sought to elucidate the role of TDP-
43 in mitochondrial dysfunction and neuronal cell death.  TDP-43, an hnRNP, is found in 
ubiquitin-positive cytoplasmic inclusions in several neurodegenerative diseases, 
including ALS.  However, little insight has been obtained into how dysregulation of this 
protein is involved in disease processes, and until very recently, TDP-43 involvement 
with mitochondrial function had not been identified.  Chapter three demonstrated that 
neither overexpression of WT or A315T mutant TDP-43 had discernible toxic effects on 
NSC-34 cells.  In addition, effective siRNA knockdown of TDP-43 also failed to induce 
cell death. It was noted that TDP-43 localized to mitochondrial fractions in NSC-34 and 
HT22 hippocampal cell lines, as well as primary cultures of astrocytes and cerebellar 
granule neurons, suggestive of a novel function for TDP-43 at the mitochondria.    
Interestingly, a very significant discovery was that siRNA depletion of TDP-43 resulted 
in a notable deficiency in mitochondrial ETC Complex I.  These findings provide an 
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important mechanistic connection between TDP-43 dysfunction and mitochondrial 
impairment. 
In an effort to further delineate these findings, the studies in chapter four sought 
to examine possible mechanisms involved in TDP-43 nuclear export. We were able to 
demonstrate that TDP-43 nuclear export is enhanced by reductions in mitochondrial GSH 
levels in NSC-34 cells.  This effect is inhibited by stable overexpression of the 
mitochondrial GSH transporter, the 2-oxoglutarate carrier (OGC), which specifically 
increases the mitochondrial GSH pool.  Furthermore, inhibition of c-Jun N-terminal 
kinase (JNK) also inhibited ethacrynic acid (EA)-induced TDP-43 nuclear export.  These 
data indicate regulatory mechanisms of TDP-43 cellular distribution and further highlight 
a relationship between mitochondrial physiology, TDP-43 dysfunction, and neuronal cell 
death. 
5.2 Discussion 
Neuronal cell death underlies several devastating neurodegenerative diseases.  It 
is consistently substantiated in literature that mitochondrial dysfunction resulting from 
oxidative or nitrosative stress can initiate neuronal cell death via apoptosis or necrosis. 
Accordingly, apoptotic cell death pathways are mechanistically linked to disruptions in 
the mitochondrial fission and fusion equilibrium, which is maintained through an intricate 
balance in expression levels and protein processing of the mitochondrial dynamics 
machinery.  As such, in order to completely understand the role of mitochondrial 
dysfunction in the process of neuronal cell death, it is crucial to evaluate how this delicate 
fission and fusion equilibrium is maintained and disturbed. 
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OPA1 is a dynamin GTPase whose main function is to facilitate fusion of the 
mitochondrial innermembrane.  In addition, OPA1 performs the fundamental tasks of 
maintaining mitochondrial cristae architecture and sequestering cytochrome c within the 
mitochondrial intermembrane space through homo-oligomerization (Cipolat et al., 2004; 
Frezza et al., 2006).  Further understanding of OPA1 regulation is essential to clarifying 
the link between disruption of mitochondrial fission/fusion and induction of apoptosis. 
OPA1 function is largely regulated through post-translational proteolytic 
processing to create long and short isoforms. These isoforms interact to form functional 
OPA1 oligomers that promote mitochondrial fusion and cristae architectural integrity 
(Landes et al., 2010a; Landes et al., 2010b). We have previously revealed a caspase-
mediated OPA1 cleavage event that results in the formation of an N-terminal truncated 
“short” form of OPA1.  Importantly, this isoform lacks a critical residue, K301, within 
the GTPase domain, rendering it unable to effectively perform its necessary functions.  
Moreover, it represents a shift in the mitochondrial fission/fusion equilibrium. In the 
studies presented here, we reveal an identical OPA1 cleavage event that occurs 
independent of caspases during oxidative and nitrosative stress-induced cell death in 
CGNs.  Notably, we also demonstrate that this OPA1 cleavage product occurs 
spontaneously in midbrain and hippocampal tissues obtained from aged mice and rats, 
suggesting that OPA1 cleavage may provide a point of convergence between oxidative 
stress, mitochondrial dysfunction, and aging; a mechanistic link that may be particularly 
relevant to the enhanced risk of neurodegeneration associated with advancing age. 
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We propose that two distinct mechanisms converge to activate the mitochondrial 
protease responsible for the N-terminal cleavage of OPA1. The first mechanism involves 
activation of a yet unknown OPA1 protease by a caspase during classical apoptotic 
conditions.  This could occur by caspase-mediated cleavage of an inhibitory regulatory 
domain, for example. Subsequently, this protease then cleaves OPA1 at a novel N-
terminal cleavage site. The second mechanism, observed under conditions of oxidative or 
nitrosative stress, involves activation of the unidentified OPA1 protease through a 
caspase-independent mechanism. This may occur via direct oxidative or nitrosative 
modification of the protease, for example, via S-nitrosylation.  Further studies are 
necessary in order to identify the mitochondrial protease involved in producing this novel 
N-terminal cleavage product. 
These findings are particularly relevant to the study of neurodegenerative 
disorders.  Many studies substantiate the impact of pathogenic proteins on the 
mitochondrial fission and fusion machinery in various disease states.  For instance 
disruptions in the mitochondrial fission and fusion equilibrium have been reported to 
occur in conjunction with proteinopathies that are found in AD, Huntington’s disease, 
and PD.  Collectively, these studies indicate that aberrant activation or suppression of the 
mitochondrial fission or fusion machinery plays a significant pathogenic role in a number 
of neurodegenerative disorders. In this regard, the OPA1 cleavage event described in this 
thesis has recently been reported to occur in a manganese (Mn)-induced Parkinsonism 
model (Alaimo et al., 2014).  Interestingly, this event was commensurate with increased 
DRP1 localization to the mitochondria, further highlighting a potential link between 
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aberrant OPA1 processing and a shift in the fission-fusion equilibrium.  Given these 
findings, it will be interesting to determine if aberrant processing of OPA1, particularly 
the generation of the N-terminal truncated cleavage product described here, is observed 
in disorders such as AD, PD, and Huntington's disease. 
In addition to mitochondrial dysfunction being a consistent finding in 
neurodegeneration, protein aggregation is also a common pathogenic mechanism in many 
neurodegenerative disorders. Specifically, TDP-43 cytoplasmic inclusions are 
pathological hallmarks of several neurodegenerative diseases, including ALS and FTLD. 
Moreover, implications of this protein’s involvement in the etiology of neurodegenerative 
diseases are widespread, as indicated by identification of TDP-43 mutations in both 
familial and sporadic forms of ALS.  TDP-43, an hnRNP, has been consistently 
demonstrated to be involved at various levels of gene expression, although many 
functions of TDP-43 remain to be determined.  Under typical conditions, TDP-43 exists 
primarily in the nucleus, but is also continuously translocated between the nucleus and 
cytoplasm (Ayala et al., 2008; Winton et al., 2008).  However, very little is known about 
the cell signaling that controls TDP-43 cellular distribution.   Furthermore, although there 
are inherent implications that dysfunction of this protein has a causal role in neuronal cell 
death, the mechanism of toxicity remains to be determined. 
LOF and GOF theories are both proposed models for TDP-43 mediated cell death 
in ALS/FTLD.  Indeed, substantial evidence exists supporting that atypical events 
surrounding this protein are an underlying cause of these neurodegenerative diseases.  
However, the list of known TDP-43 functions is substantial and certainly not exhaustive, 
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which proves to be an added challenge in discerning putative GOF or LOF effects of 
TDP-43 dysfunction.  Given these considerations, understanding the definitive 
mechanisms behind TDP-43 mediated neuronal cell death will undoubtedly be a complex 
process. 
In the studies presented in this thesis, we used overexpression and siRNA 
knockdown methods to approximate GOF and LOF effects in vitro.  Each approach failed 
to elicit overt neuronal cell death or cause any morphological toxic effects.  However, 
these findings are not surprising, given the conflicting reports on this topic, and perhaps 
further substantiate the multi-faceted nature of TDP-43 mediated toxicity.  We were able 
to demonstrate that WT and mutant TDP-43 partially localize to the mitochondria, which 
became substantiated in several other studies (Hong et al., 2012; Wang et al., 2013).  It 
has also been reported that impairments in mitochondrial dynamics caused by 
overexpression of TDP-43 (WT or mutant), can be rescued through overexpression of the 
mitochondrial fusion protein MFN2, which establishes a novel link between TDP-43 
function and mitochondrial dynamics (Wang et al., 2013).  Additionally, we also 
demonstrated significant deficits in mitochondrial Complex I upon depletion of cellular 
TDP-43 levels.  Interestingly, other studies demonstrate that overexpression of WT or 
mutant TDP-43 cause a defect in mitochondrial Complex I activity (Hong et al., 2012; Lu 
et al., 2012).  Furthermore, dysfunctions in mitochondrial dynamics, membrane potential 
and cristae morphology have been observed upon depletion of TDP-43 (Wang et al. 
2013).  In lieu of similar phenotypes resulting from both overexpression and depletion of 
TDP-43, it is an interesting concept that perhaps mitochondrial health and function is 
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susceptible to a fragile balance of TDP-43 levels and function.   Overall, these recent 
findings are noteworthy in that they establish a relationship between TDP-43 and 
mitochondrial function.   
 TDP-43 functions are largely comprised of modulating gene expression through 
direct DNA and RNA binding.  We propose that TDP-43 may be involved in regulation 
of mitochondrially encoded ETC components, and that disruption in TDP-43 function 
results in a disturbance in the production of these essential proteins.  We suggest that 
nuclear export of TDP-43 is triggered as a means to regulate transcription of damaged 
mitochondrial components, and that nuclear export of TDP-43 during mitochondrial 
catastrophe (as is observed during neurodegeneration) is increased to levels that 
overwhelm cytoplasmic protein trafficking systems.  Subsequently, TDP-43 aggregates 
form and become ubiquitinated by proteasome machinery in an effort to combat these 
inclusions.  In the context of mutant TDP-43 effects, we surmise that dysfunctional forms 
of TDP-43 are not able to properly participate in repair of damaged ETC components.  
This deficiency would likely cause subsequent increases in ROS production, causing 
further damage to the mitochondria. Interestingly, a recent study supports this theory, in 
which mice containing a heterozygous mutant TDP-43 knock-in (A315TKi) developed 
insoluble TDP-43 protein aggregates and disruptions in mitochondrial cristae architecture 
(Stribl et al.,  2014), suggesting that expression of mutant TDP-43 at physiological levels 
results in TDP-43 histopathology and impairment in mitochondrial structure. 
Heterozygous TDP-43(A315TKi) mutants lost 10% of their body weight and developed 
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insoluble TDP-43 protein starting as early as 3 months after birth, a pathology that was 
exacerbated with age.             
Finally, we report that TDP-43 nuclear export is enhanced by reductions in 
mitochondrial glutathione (GSH) levels in NSC-34 cells.  This event is largely prevented 
by specifically increasing the mitochondrial GSH pool through stable overexpression of 
the mitochondrial GSH transporter OGC.  In addition, we demonstrate that, inhibition of 
c-Jun N-terminal kinase (JNK), but not p38 MAP kinase, effectively ameliorates EA-
induced TDP-43 nuclear export, thus implicating specific cell signaling factors that are 
involved in GSH depletion-mediated TDP-43 nuclear export.  Moreover, other studies 
have demonstrated that oxidative stress-induced TDP-43 localization to cytoplasmic 
stress granules (SGs) preceded ubiquitin-positive TDP-43 aggregations, and that SG 
formation, but not TDP-43 cytoplasmic localization, was inhibited by incubation with a 
JNK inhibitor (Meyerowitz,et al., 2011; Parker et al., 2012).  In contrast to our reports, 
TDP-43 nuclear export was not affected by JNK, yet aggregate formation, once in the 
cytoplasm, was affected by JNK signaling.  These differences in the regulation of nuclear 
export by JNK may relate to the different insults used to induce oxidative stress; we used 
EA-induced GSH depletion whereas other groups used paraquat, which has a much more 
complex mode of inducing oxidative damage.  Collectively, these data indicate a complex 
relationship between TDP-43 cellular localization and JNK signaling. Furthermore, our 
findings suggest a novel method of regulating TDP-43 cellular distribution and further 
highlight a relationship between mitochondrial physiology, TDP-43 dysfunction, and 
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Appendix A: Abbreviations 
AD, Alzheimer's disease 
ADOA-1,  autosomal dominant optic atrophy 1 
ALS, Amyotrophic lateral sclerosis 
APP, amyloid precursor protein 
CC, coiled-coil 
CCCP, carbonyl cyanide m-chlorophenyl hydrazone 
CGNs, cerebellar granule neurons 
CIC, citrate carrier/tricarboxylate carrier 
CNS, central nervous system 
DIC, dicarboxylate carrier 
Dnm1, dynamin 1 
DRP1, dynamin-related protein 1 
EA, ethacrynic acid 
ETC, electron transport chain 
FIS1, fission 1 
FTLD, Fronto temporal lobar degeneration 
GED, GTPase effector domain 
GPx, glutathione peroxidase 
GR, glutathione reductase 
GSH, glutathione 
H2O2, hydrogen peroxide 
HD, Huntington's disease 
HR, heptad repeats 
JNK, c-Jun N-terminal kinase 
MAPK, mitogen activated protein kinase 
MFF, mitochondrial fission factor 
DRP11/2, Mitofusin 1/2 
MiD49/51, mitochondrial dynamics protein 
MIEF1 , mitochondrial elongation factor 1 
MIS, mitochondrial import signal 
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mtDNA, mitochondrial DNA 
MTS, mitochondrial targeting sequence 
NES, nuclear export signal 
NLS, nuclear localization signal 
OGC2, oxoglutarate carrier 
OPA1, Optic atrophy 1 
OXPHOS, oxidative phosphorylation 
PARL, presenilin-associated rhomboid-like protease 
PD, Parkinson's disease 
PH, plextrin homology 
RNS, reactive nitrogen species 
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ROS, reactive oxygen species 
SOD, superoxide dismutase 
TDP-43, TAR-DNA binding protein 
TM, transmembrane domain 
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